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AnAtoMy
The Achilles tendon inserts proximally to the gastrocnemius and soleus muscles and 
distally it attaches to the tuber calcanei. Unlike other tendons in the leg, the Achilles 
tendon lacks a synovial sheath, but is surrounded by a peritendinous sheet called the 
paratenon which functions as an elastic sleeve to reduce friction.1
Aetiology
Overuse injury of the Achilles tendon was firstly described by Albert in 1893.2 Patients 
present with pain in the tendon after loading activities, and when the condition become 
chronic the pain also exists during loading activities and in daily activities. In 1998, Khan 
argued that the combination of pain, swelling, and impaired performance should be 
labelled tendinopathy.3 The pathogenesis pathways of Achilles tendinopathy is highly 
heterogeneous. Many risk factors have been identified, for example: age, circulating and 
local cytokine levels, gender, biomechanics and body composition.4
Histopathology of symptomatic tendons shows a degenerative non-inflammatory 
process with a disorganized collagen structure in most cases. However, these abnor-
malities are also found in 34% of asymptomatic tendons.5 This finding supposes that the 
intratendinous degenerative changes may not be directly the cause of pain.
Different hypothesis are described in literature about the origin of pain in tendinopathy. 
One hypothesis is that painful tendons are only the tip of the iceberg after a continuum 
from physiology to overt clinical presentation. The neurogenic hypothesis is based on 
stimulation of neuropeptides like substance P resulting in tissue breakdown and release 
of inflammatory mediators.6 It has frequently been hypothesized that neovasculariza-
tion and the accompanying nerves are the source of pain in chronic midportion Achilles 
tendinopathy.7 Recently an additional theory was described about the stiffer plantaris 
longus tendon forming adhesions to the Achilles tendon as a source of pain.8,9
epideMiology
Tendinopathy is common in athletes. Especially in runners high incidence rates (incidence 
rate 9.1-10.9%) are reported.10 Incidence rates in general population are lacking. With the 
high prevalence in athletes, overuse seems to be an important risk factor for developing 
Achilles tendinopathy. Interestingly degenerative changes in Achilles tendons are also 
observed in wild animals kept in cavity.1 While the incidence was related to age, the major 
cause for the tendon degeneration was decreased activity from being caged.11
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clinicAl presentAtion
As noticed above, midportion Achilles tendinopathy is a clinical diagnosis that can be 
made in presence of a painful swelling of the Achilles tendon 2-8 cm from the calcaneal 
insertion which impede loaded activities.12
outcoMe scores
A validated outcome measure to assess the clinical severity of decreased activity and 
symptoms in Achilles tendinopathy is the Victorian Institute of Sports Assessment-
Achilles (VISA-A) questionnaire.13,14 The VISA-A questionnaire (0–100) consists of eight 
questions and includes the three domains of pain, function in daily living and sporting 
activity.
iMAging
Tendons can be imaged by ultrasound and magnetic resonance imaging (MRI). Fiber 
disorganisation, tendon swelling, fluid accumulation or fatty degeneration can be 
discriminated with MRI.15 The superficial position of the Achilles tendon under the skin 
makes it highly suitable for ultrasound examination. With regular ultrasound, thickness 
of the tendon, degenerative areas, calcifications and abnormalities of the peritendinous 
space can be visualised . With ultrasound Doppler the ingrowth of new blood vessels 
into tendinopathic areas can be detected.16 New imaging technique like sonoelastog-
raphy and ultrasonographic tissue characterisation (UTC) were developed last years.17,18
therApy
Initially it was thought that symptoms of tendinopathy might improve without interven-
tion after approximately one year.19 However, prognostic studies on a wait-and-see re-
gime are scarce. Two studies reported inferior results of a wait and see policy compared 
to eccentric exercise and shock wave treatment.20 Eccentric exercises are best studied 
of all treatment options in Achilles tendinopathy. The eccentric exercise starts with a 
heel lift, after that the eccentric drop is performed with the injured leg. During 12 weeks 
patients are instructed to perform 180 repetitions daily, despite the presence of pain.21 
Different systematic reviews show beneficial effects of a 12-week eccentric exercise 
protocol.22,23 
General introduction 11
ch
ap
te
r 1
While corticosteroid injections are still used for the treatment of tendinopathy, there 
is emerging evidence that those cause significant long-term harms to tendon tissue and 
cells.24 Sclerosing injections are a popular technique targeting the neovascularization 
of the tendon. However large randomized trials are lacking and therefore no conclu-
sion can be made on this therapy.25 Injection of platelet-rich plasma (PRP) to release 
growth factors into degenerative tendon areas, is increasingly used in the field of sports 
medicine. However different systematic reviews shows a lack of benefit over placebo 
treatments.26,27 The use of cell based therapies is under active investigation for sports 
injuries. Lui reported in their systematic review on cell therapy nine pre-clinical and 
two clinical studies. They found improvement of tendon architecture in histology and 
in sonographic/MRI examination, and increase in functional and biomechanical perfor-
mance. However the available data is insufficient to result in hard conclusion.28
The literature on the use of orthotics in Achilles tendinopathy is scarce. A recent re-
view showed weak evidence that foot orthotics are equivalent to physical therapy. The 
effectiveness of heel raises for Achilles tendinopathy is unknown.29
Extracorporeal shockwave therapy (ESWT), a physical therapy modality that uses pres-
sure waves to treat tendinopathy. While in vitro studies often show the effects of ESWT 
on tendon tissue, results of clinical studies are inconsistent.30 
Low Level Laser Therapy (LLLT) is thought to decrease inflammation, increase fibro-
blast activity leading to improved collagen production. A systematic review reported 
conflicting evidence of the effectiveness of LLLT in the treatment of tendinopathy.31
All investigated operative methods were demonstrated to improve patients s condi-
tions, though success rates varied between operative techniques. The complication rate 
differs between used techniques. Minimal invasive operative techniques seem to be 
related with fewer complications but open techniques report on higher success rates. 
Results vary between subjects according to sex and activity level.32
AiMs And outline of this thesis
This thesis aims at elucidating the effect of different treatment options in midportion 
Achilles tendinopathy, with optimizing current diagnostic methods. A better under-
standing will have positive consequences for the patients.
First we tried to outline the size of the problem, by determining the incidence of 
mid-portion Achilles tendinopathy in the general practitioner population in the Neth-
erlands (chapter 2). To evaluate the effect of different post injection protocols after 
intratendinous injections on the spread of the injected substance, a cadaveric study 
was performed and described in chapter 3. The clinical relevance of neovasculariza-
tion measured with Doppler ultrasound was evaluated in a prospective cohort study 
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(chapter 4). As degenerative tendon injuries are prevalent in people with diabetes, we 
conducted a case-control study to determine whether diabetic patients have poorer 
ultrasonographic structure in their Achilles tendons compared to age-matched controls 
(chapter 5). In chapter 5 we also investigated if age, BMI, and sports activity were associ-
ated with Achilles tendon structure. Mid- and long term effects of the eccentric exercise 
protocol were evaluated in chapter 6.1 and 6.2. The one year follow-up of a doubled 
blinded randomised controlled trial on platelet rich plasma therapy is described in 
chapter 7. 
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AbstrAct
background: Achilles tendon disorders, like Achilles tendinopathy, are very common 
among athletes. In the general population, however, knowledge about the incidence of 
Achilles tendinopathy is lacking.
design: Cross-sectional study.
Methods: In a cohort of 57.725 persons registered in primary care, the number of 
patients visiting the general practitioner (GP) with diagnosis of mid-portion Achilles 
tendon problems was counted using computerized registration networks of GPs in 
2009. Subsequently, the authors assessed associations of these rates with demographic 
characteristics.
results: The incidence rate of Achilles tendinopathy is 1.85 per 1,000 Dutch GP regis-
tered patients. In the adult population (21–60 years), the incidence rate is 2.35 per 1,000. 
In 35% of the cases, a relationship with sports activity was recorded.
conclusion: This is the first report on incidence rates of mid-portion Achilles tendinopa-
thy in general practice. With an incidence of 1.85 per 1,000 registered persons, Achilles 
tendinopathy is frequently seen by GPs. The actual incidence might even be higher due 
to study limitations. More research on the frequency of this injury is required.
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introduction
Achilles tendon problems frequently occur in athletes and are supposed to be common 
as well in the general population. The frequency of Achilles tendinopathy in athletes has 
been reported in several studies. Elite long-distance runners have a lifetime risk of 52%, 
and the lifetime incidence of 416 participants of Finnish conscription was 5.9%.1 Others 
reported annual incidence rates of Achilles tendon disorders of 7% and 9%, respectively, 
in top-level runners.2  3 Among the military population, an incidence of 2.98 per 1,000 
person years was found.4 A cohort study of 725 male marathon runners reported an 
incidence of 7.4% in the month before the Rotterdam marathon.5 While these frequency 
rates were recorded in the sporting population, Achilles tendinopathy is not always asso-
ciated with excessive physical activity; it is also seen in patients who do not participate in 
sports.6–8 To our knowledge, there are no studies on the incidence of Achilles tendinopa-
thy in the general population. Incidence rates are useful for studying trends in occurrence 
of diseases, future intervention studies, and for burden of disease estimates. To obtain 
this incidence rate, a cross-sectional study within the Dutch general practice setting was 
performed. In the Netherlands, every non-institutionalised inhabitant is registered with a 
general practitioner. In case of a health problem, the general practice is intended to be a 
gatekeeper to specialist care. The primary aim of this study was to ascertain the frequency 
of mid-portion Achilles tendinopathy seen in the general practitioner (GP) setting.
Methods
In this cross-sectional study, data were obtained from computerised registration systems 
of Dutch GPs. General practices were approached for participation by mail and telephone. 
After permission, the researcher visited the practices. During this visit, all electronic pa-
tient files for consultations in 2009 were systematically searched under supervision of the 
GP. GPs in the Netherlands use International Classification of Primary Care (ICPC)9 codes 
to register the reason for the visit. These codes include disease-specific codes as well as 
complaint specific codes. There is, however, no specific code for Achilles tendinopathy. 
Another sensitive way of searching for certain diagnosis is to use diagnosis specific words 
in the free text of the records. We searched for the term achil to find as many records 
describing the diagnosis of Achilles tendinopathy (eg, terms as Achillodynia could also 
be found). Medical files of the found records were read by a single researcher (CvdB) to 
assess whether they met the inclusion criteria. For the diagnosis of Achilles tendinopathy, 
a description of pain in the Achilles tendon above the insertion was required. Lack of this 
description resulted in exclusion. When the first contact with the GP for complaints was in 
the year 2009 without a previous visit in 2008, the patient was scored as an incident case. 
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In addition, age, gender, date of presentation and sports activity (related to complaints) 
were recorded if these had been recorded in the medical record. The medical record was 
also screened for diabetes mellitus (DM) type 1 and 2. Statistical analysis was performed 
using SPSS (version 17). Incidence rates were calculated separately for age group and sex.
results
Between February 2011 and April 2011, 128 general practices were approached. Four-
teen practitioners did not answer repeated phone calls and 94 GPs refused to participate. 
Twenty GPs at different geographic locations responded positively to the invitation and 
were visited by the researcher. The 20 participating practices contained 57.725 regis-
tered persons, with an average of 2,886 persons in each practice (range 1,757–6,486). 
The research strategy “Achil” in the free text resulted in 277 cases in 2009. After screening 
the medical files, 116 cases of mid-portion Achilles tendinopathy could be recorded. 
Frequently reported other Achilles tendon disorders were insertional disorder, lash 
and bursitis. The prevalence rate of Achilles tendinopathy is 2.01 per 1,000 registered 
patients. Of these 116 prevalent cases, 9 patients had visited the general practitioner 
in 2008 for the same reason, resulting in 107 incident cases in 2009. The incidence rate 
for mid-portion Achilles tendinopathy is 1.85 per 1,000 registered patients. The 107 
incident cases contained 56 females (52.3%) and 51 males (47.7%). Age- and sex-specific 
incidence rates are given in table 1. The overall incidence rate in the adult population 
between 21 and 60 years is 2.35 per 1,000. The mean age at time of presentation within 
the cases was 43.4 years (range 7–85 years). Mid-portion Achilles tendinopathy equally 
affects women and men. Mean duration of symptoms at presentation (reported in 39 
cases) was 11.3 weeks (range 1–52). In 37 cases (34.6%), a relationship with sports activ-
ity was recorded. Ten patients (9.3%) were known to have DM—two patients with type 
1 DM and eight patients with type 2 DM. Table 2 shows the patient characteristics of the 
case group compared with the study population and the Dutch population.
table 1: Age and sex specific incidence rates for Achilles tendinopathy in 20 general practices.
Age at time of diagnosis
< 20 years 21-40 years 41-60 years > 60 years total
n persons ir n persons ir n persons ir n persons ir n persons ir
Male 7 6371 1.1 13 7289 1.8 24 8459 2.8 7 5642 1.2 51 27761 1.8
Female 6 6342 0.9 21 7584 2.8 18 8996 2.0 11 7042 1.6 56 29964 1.9
Total 13 12713 1.0 34 14873 2.3 42 17455 2.4 18 12684 1.4 107 57725 1.9
n = number of persons with Achilles tendinopathy. Persons = number of registered persons. IR, incidence 
rate = number cases per 1000 registered persons.
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discussion
This is the first study presenting incidence rates of Achilles tendinopathy in the general 
practice. The overall incidence rate is 1.85 per 1,000 registered persons per year, and for 
the adult population it is 2.35. There are no other studies on the incidence rates of Achilles 
tendinopathy in the general population to compare these results with. The prevalence 
rate was higher than that for another tendinopathy like lateral epicondylitis of 1.3% 
(men) and 1.1% (women) in 9,696 persons registered at two general practitioners.10 The 
incidence rates in our study are lower than the incidence of 2.98 found in the military 
population4 and than the annual incidence 7% and 9% in top-level runners.2 3 While it 
seems plausible that the incidence rate of Achilles tendon injuries is higher in athletes 
than within a more general population, only in 35% of the cases in our study was a 
relationship with sports activity described. Intrinsic risk factors such as body weight and 
insulin resistance might also play a role.11 Although we could not assess information on 
body weight, the diagnosis of DM was available from the medical records. DM seemed 
more prevalent among the incident cases compared with the general Dutch population 
(table 2). However, more research is needed to draw any conclusions on a causative as-
sociation The minor difference between the incidence and prevalence rate suggests that 
most patients only visit their GP once with their Achilles tendon problems. This might 
be because of a short duration of symptoms or that the patients go to a physiotherapist 
or sports physician afterwards. This cross-sectional study has some limitations, due to 
which the actual incidence of Achilles tendinopathy in the general population is prob-
ably higher than observed in this study. Firstly, not every person with a certain com-
table 2: Patient characteristics in the cases with Achilles tendinopathy, in the total study population, and in 
the Dutch population (as recorded by CBS, Statistics Netherlands http://www.cbs.nl 2009).
patients with Achilles tendinopathy
(95% confidence interval)
n=107
study population 
n=57.725
dutch population  
in year 2009
n=16.485.787
Gender
male 47.7% (95% CI, 38.0-57.3) 48.1% 49.5%
female 52.3% (95% CI, 42.7-62.0) 51.9% 50.5%
Diabetes Mellitus 9.3% (95% CI, 3.7-15.0) 4.1%
Type 1 1.8% (95% CI, 0-4.5) 0.8%
Type 2 7.5% (95% CI, 2.4-12.5) 3.3%
Age groups
<20 years 12.1% (95% CI, 5.9-18.4) 22.0% 23.9%
21-40 years 31.8% (95% CI, 22.8-40.7) 25.8% 25.7%
41-60 years 39.3% (95% CI, 29.8-48.7) 30.2% 35.5%
>60 years 16.8% (95% CI, 9.6-24.0) 22.0% 15.0%
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plaint will visit a healthcare professional. In a cross-sectional population-based study, 
Picavet et al. reported that approximately 50% of the patients with musculoskeletal 
complaints visited a healthcare professional.12 However, those with severe or persistent 
complaints will probably seek healthcare. Second, while most patients in the Dutch 
healthcare system will visit their GP before being referred to a therapist or specialist, 
since 2006 patients can visit a physiotherapist or sports physician without referral by a 
GP. It would be interesting to know the incidence rates of Achilles tendinopathy within 
the patient population of the Dutch physiotherapists and sports physicians as well, but 
since the denominators of these populations are unknown, no exact incidence rates 
could be obtained. Finally, because there is no specific registration code (ICPC) available 
for Achilles tendinopathy, GPs register this injury using other or more general codes. The 
search strategy “Achil” is considered to be highly sensitive for Achilles tendon problems; 
however, there is a possibility of missing some cases. Furthermore, the 13 patients less 
than 20 years old might have a growth-related disorder rather than mid-portion Achilles 
tendinopathy. In concordance with other studies,4,13 most cases were encountered in the 
middle-aged population (age group 41–60 years). It is unclear why Achilles tendinopa-
thy is more frequent within this age group. A possible explanation might be a higher 
incidence of degenerative tendons, susceptible to overuse, in the elderly.
conclusion
In conclusion, this is the first study to report an incidence rate of Achilles tendinopathy 
in the general population. With an incidence of 1.85 per 1,000 registered patients, and 
of 2.35 in the adult population, more research on pathophysiology and therapy is war-
ranted.
Incidence of Achilles tendinopathy in general population 23
ch
ap
te
r 2
references
 1. Kujala UM, Sarna S, Kaprio J. Cumulative incidence of achilles tendon rupture and tendinopathy 
in male former elite athletes. Clin J Sport Med 2005;15:133–5.
 2. Johannsen FE, Gam AN. [Achillodynia is not just a sports injury]. Ugeskr Laeg 2010;172:3325–9.
 3. Lysholm J, Wiklander J. Injuries in runners. Am J Sports Med 1987;15:168–71.
 4. Clement DB, Taunton JE, Smart GW. Achilles tendinitis and peritendinitis: etiology and treatment. 
Am J Sports Med 1984;12:179–84.
 5. Van Middelkoop M, Kolkman J, Van Ochten J, et al. Prevalence and incidence of lower extremity 
injuries in male marathon runners. Scand J Med Sci Sports 2008;18:140–4.
 6. de Vos RJ, Weir A, van Schie HT, et al. Platelet-rich plasma injection for chronic Achilles tendinopa-
thy: a randomized controlled trial. JAMA 2010;303:144–9.
 7. Paavola M, Orava S, Leppilahti J, et al. Chronic Achilles tendon overuse injury: complications after 
surgical treatment. An analysis of 432 consecutive patients. Am J Sports Med 2000;28:77–82.
 8. Schepsis AA, Jones H, Haas AL. Achilles tendon disorders in athletes. Am J Sports Med 
2002;30:287–305.
 9. Lamberts H, Wood M, Hofmans-Okkes I. The International Classifi cation of Primary Care. Oxford: 
Oxford University press 1987.
 10. Walker-Bone K, Palmer KT, Reading I, et al. Prevalence and impact of musculoskeletal disorders of 
the upper limb in the general population. Arthritis Rheum 2004;51:642–51.
 11. Gaida JE, Ashe MC, Bass SL, et al. Is adiposity an under-recognized risk factor for tendinopathy? A 
systematic review. Arthritis Rheum 2009;61:840–9.
 12. Picavet HS, Schouten JS. Musculoskeletal pain in the Netherlands: prevalences, consequences 
and risk groups, the DMC(3)-study. Pain 2003;102:167–78.
 13. Cook JL, Khan KM, Purdam C. Achilles tendinopathy. Man Ther 2002;7:121–30.

C h a p t e r  3 C o m p a r i s o n  o f 
p o s t i n j e c t i o n  p r o t o c o l s 
a f t e r  i n t r a t e n d i n o u s 
A c h i l l e s  p l a t e l e t - r i c h 
p l a s m a  i n j e c t i o n s : 
A  c a d a v e r i c  s t u d y
J.I. Wiegerinck, S. de Jonge, M. C. de Jonge, G.M. Kerkhoff s, 
J.A.N. Verhaar and C.N. van Dijk
J Foot Ankle Surg. 2014 Nov-Dec;53(6):712-5
26 Chapter 3
AbstrAct
The purpose of the present investigation was to evaluate the distribution of intraten-
dinous injected platelet-rich plasma (PRP) after 15 minutes of prone resting versus 
immediate manipulation simulating weightbearing. Ten cadaveric lower limbs were 
injected under ultrasound guidance with PRP dyed with India blue ink. The dyed PRP 
was injected into the mid-portion of the Achilles tendon, after which 5 specimens 
were placed in the prone position for 15 minutes (simulating rest) and the remaining 
5 specimens were manipulated through100 cycles of ankle dorsiflexion and plantar 
flexion (simulating walking). Thereafter, the specimens were dissected, and the distribu-
tion of the India blue dye was ascertained. In the simulated rest group, every specimen 
showed dyed PRP in the Achilles tendon and in the space between the paratenon and 
tendon. The median craniocaudal spread of the PRP was 140 (range 125 to 190) mm. 
In 4 of the simulated rest tendons (80%), the distribution of PRP extended across the 
entire transverse plane width of the tendon. In the simulated motion group, every 
specimen showed dyed PRP extending across the entire transverse planewidth of the 
tendon and in the space between the paratenon and tendon. The median craniocaudal 
spread was 135 (range 115 to 117) mm. No statistically significant difference was found 
in the amount of craniocaudal spread between the simulated motion and rest groups. In 
conclusion, it does not appear to matter whether the ankle has been moved through its 
range of motion or maintained stationary during the first 15 minutes after PRP injection 
into the mid-portion of the Achilles tendon. The precise meaning of this information in 
the clinical realm remains to be discerned.
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introduction
The possible healing effect of platelet-rich plasma (PRP) on Achilles tendinopathy 
depends on the influence of the platelets on the damaged tenocytes and adequate 
delivery of the PRP at the lesion site.1–5 A previous study has confirmed that PRP reaches 
the designated anatomic location after ultrasound-guided injection into and around 
the Achilles tendon (AT).6 In addition to the role of the specific injection location, the 
postinjection protocol could be of importance.6 Little is known about the distribution 
of the fluid after injection into the AT.6 The PRP, injected at the desired location, might 
gradually disperse to other locations under the influence of gravity or ankle movement 
after injection. Different postinjection protocols have been described in clinical studies 
reporting on the effects of PRP in tendinopathy.7–12 One postinjection protocol advo-
cated immediate weightbearing. In contrast, others7 have advised maintaining a prone 
position for at least 10 to 15 minutes after injection.11,12 Finally, partial weightbearing for 
the first few days after the injection has also been recommended.8-10 These considerable 
differences could cause variation in the clinical outcomes after PRP therapy for Achilles 
tendinopathy.1,12 The primary purpose of the present study was to evaluate the effect of 
2 different postinjection protocols after intratendinous, mid-portion AT PRP injection 
on the spread of PRP in and around the AT. We measured the spread of the PRP after 
simulated ankle motion and compared it with the spread after a 15-minute postinjec-
tion period of rest in a cadaveric model. Our secondary aim was to compare the results 
of our investigation with those described in a previously published report.6
MAteriAls And Methods
In the present cadaveric study, 10 lower limbs were injected with India blue-dyed PRP. 
The PRP was injected into the AT. The duration of each injection was timed, with the 
time starting as the radiologist (M.J.) received the syringe with dyed PRP and ending 
as the radiologist signaled the injection had finished. After injection, 5 limbs (50%) 
were placed in the prone position for 15 minutes. The other 5 (50%) were manipulated 
manually for 5 minutes through 100 cycles of ankle dorsiflexion and plantar flexion in 
an effort to simulate the motion associated with immediate weightbearing ambulation 
in the clinical setting. The specimens were randomly assigned in equal size groups 
using a computerized randomization program to either the simulated motion or rest 
group. Specifically, the postinjection cadaveric ankle was maximally dorsiflexed from 
the neutral position (foot at 90° to the leg) and maximally plantar flexed to the soft tissue 
end range of motion in each direction, with each excursion from the neutral position to 
maximum dorsiflexion and then to maximum plantar flexion and back to the neutral 
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position, accounting for 1 cycle. Thereafter, an orthopedic surgeon (G.K., C.D.) carefully 
dissected each specimen, and the presence of the dyed PRP was documented in regard 
to its gross anatomic distribution in and about the AT. Also, the extent of the spread from 
the site of the injection in the mid-portion of the AT was measured.
specimen demographics
The present study included 10 fresh frozen cadaveric lower limbs (4 [40%] male and 
6 [60%] female specimens). The median age of the specimens was 74 (range 58 to 83) 
years. None of the specimens displayed evidence of previous surgery on any part of the 
extremity, and we did not have any information regarding any specific AT pathologic 
features. To be included in the present study, inspection of the cadaveric specimen had 
to reveal the absence of any apparent scarring in the AT region.
prp production, coloring, and injection technique
For meaningful comparison with previous studies6,13, we chose to use a PRP production, 
coloring (dyeing), and injection technique that has been previously described.6 The 
PRP was prepared at the clinical chemistry laboratory of the Academic Medical Center 
(Amsterdam, The Netherlands). The process involved the use of 210 mL of donor citrate 
blood (0.0109 M), which was used to make 50 mL of PRP. The blood was retrieved using 
an open system without storing the whole blood, after which the blood was centrifuged 
at 180g for 15 minutes at 20 C (Rotina 46 RS Hettich Zentrifugen, Tuttlingen, Germany). 
After centrifuging, the PRP was removed using a pipette, and 1.25 mL of India blue dye 
was added to the 50-mL aliquot of PRP, binding directly with the plasma, enabling a 
thorough detection of PRP with the bound dye in the tissues after injection. The ankles 
were placed in the prone position (Fig. 1). The designated injection location was recorded 
before the injection. A medial approach to the mid-portion of the AT was used, because 
this is commonly used in clinical practice to avoid damage to the sural nerve. A Philips 
iU22 ultrasound machine with a 17.5-mHz transducer (Philips Healthcare, Philips Medi-
cal Systems, Eindhoven, The Netherlands), tuned to the musculoskeletal presetting, was 
used to visualize the tendon for accurate placement of the injection into the substance of 
the AT and to determine whether any of the specimens displayed a defect identifiable by 
ultrasonography. Each of the cadavers was injected intratendinously at the mid-portion 
level (2 to 6 cm proximal to the AT insertion into the calcaneus).14 The injections were 
not specifically directed toward a tendon lesion, because hypoechogenicity (irregular or 
few internal echo patterns) of the AT was not found in any of the specimens. The total 
injection, consisting of 5 mL of dyed PRP, was administered in 3 separate portions of 
approximately 1.5 mL, placed approximately 1.5 cm apart using a peppering technique, 
as previously described for the in vivo treatment of Achilles tendinopathy.7 The same 
16-gauge needle and 5-mL syringe were used for each of the 3 injections, and the ul-
Cadaveric study on postinjection protocols in Achilles tendons 29
ch
ap
te
r 3
trasound transducer was used to guide the transverse plane injection of the dyed PRP. 
After positioning the tip of the needle in the desired intratendinous location, the dyed 
PRP was injected. Thereafter, the specimen was either manipulated to simulate motion 
or allowed to rest in the prone position, similar to the clinical setting,7 for 15 minutes.
Anatomic dissection
Just as with the PRP production and injection technique, the anatomic dissection of 
the specimens was performed using a previously described technique.6 The technique 
preserves the anatomic relationship among the paratenon, AT, and surrounding tissues 
during dissection (Fig.  2). The dissection entailed a longitudinal skin incision that ex-
tended from the distal margin of the gastrocnemius muscle to the calcaneal insertion of 
the AT (Fig. 3). The most proximal and most distal grossly visible extent was measured 
from the point of injection of the dyed PRP using a ruler and confirmed by 2 observers. 
To fully appreciate the spread of the dyed PRP, the AT was transected proximally, distally, 
and at the level of the injection point (Fig. 4).
figure 1: Placement of cadaveric ankles for injection procedure and location of ultrasound-guided injections.
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results
A statistical description of the results is presented in Table 1. In the simulated rest group, 
the median duration of the injection of the dyed PRP was 111 (range 99 to 164) seconds. 
Moreover, in the rest group, the median craniocaudal gross visible spread of the dyed 
PRP after 15 minutes in the prone position was 140 (range 125 to 190) mm. All the 
specimens displayed dyed PRP in the AT at the tendon’s insertion into the calcaneus and 
proximal to the mid-portion injection site and in the area between the paratenon and AT 
(Fig. 3). In 4 (80%) of the 5 tendons, the dyed PRP was distributed throughout the entire 
coronal plane of the AT (Fig. 4). Three of the tendons (60%) showed grossly visible traces 
of the dyed PRP in the pre-Achilles fat pad, and none of the tendons in the rest group 
showed infiltration of the dyed PRP into the plantaris tendon. In the simulated motion 
group, the median duration of the injection of the dyed PRP was 124 (range 99 to 131) 
seconds. Moreover, in the simulated motion group, the median craniocaudal gross vis-
ible spread of the dyed PRP after 100 cycles of dorsiflexion and plantar flexion motion 
was 135 (range 115 to 170) mm. In all 5 of these tendons, the dyed PRP was distributed 
throughout the entire coronal plane of the AT and in the area between the paratenon 
and AT. Four of the simulated motion tendons (80%) showed grossly visible traces of the 
dyed PRP in the pre-Achilles fat pad (Fig. 5), and none showed infiltration of the dyed 
PRP into the plantaris tendon.
figure 2: Anatomic dissection of the cadav-
eric lower leg showing infiltration of the Achil-
les tendon with India blue-dyed platelet-rich 
plasma.
figure 3: Anatomic dissection of the cadaveric lower 
leg showing infiltration of the Achilles tendon with India 
blue-dyed platelet-rich plasma spreading up to the inser-
tion of the Achilles tendon onto the calcaneus.
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discussion
The present study evaluated the effect of 2 different postinjection protocols after injec-
tion of PRP, dyed with India ink, into the mid-portion of cadaveric ATs. In 1 group of 
ATs, motion was simulated using ankle 100 cycles of dorsiflexion and plantar flexion; 
in the other group, the specimen was maintained stationary in the prone position for 
15 minutes before dissection and identification of the spread of the dyed PRP. Previous 
studies have evaluated the feasibility of fluid injections into and around different ankle 
figure 5: Anatomic dissection of the cadaveric lower 
leg showing infiltration of India blue-dyed platelet-rich 
plasma throughout the Achilles tendon. The plantaris 
tendon was not infiltrated with platelet-rich plasma 
because it has a separate tendon sheath. Note how the 
platelet-rich plasma spreads throughout the insertion of 
the Achilles tendon onto the calcaneus.
figure 4: Anatomic dissection of the cadaveric 
lower leg showing infiltration of India blue-dyed 
platelet-rich plasma throughout the transverse 
plane of the Achilles tendon.
table 1: Comparison of the results from simulated rest and manipulation groups after injection with India 
blue-dyed platelet-rich plasma (n = 10 cadaveric lower extremities).
Variable rest (n = 5) Manipulation (n = 5) overall
Craniocaudal spread (cm)
 Median 140 135 145
 Range 125 to 190 115 to 170 115 to 190
Dyed PRP between paratenon and AT 5 (100) 5 (100) 10 (100)
Dyed PRP evident in AT 5 (100) 5 (100) 10 (100)
Dyed PRP in plantaris tendon 0 (0) 0 (0) 0 (0)
Dyed PRP in pre-Achilles fat space 3 (60) 4 (80) 7 (70)
Duration of injection (s)
 Median 111 124 115
 Range 99 to 164 99 to 131 99 to 164
Abbreviations: AT, Achilles tendon; PRP, platelet-rich plasma.
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ligament and the feasibility and accuracy of PRP injections into and around the AT.6,13 To 
our knowledge, this is the first study comparing postinjection protocols on the spread of 
PRP after intratendinous injection. As a consequence of this absence, the postinjection 
protocols have differed widely among therapeutic studies on the effect of PRP.7,12 With 
the varying results from these studies and the accuracy of the injections in mind, the 
postinjection protocol could have significant influence on the outcomes of these stud-
ies.4,7–9,12,15–19 Because most intratendinous injection methods are currently comparable, 
it would be interesting to examine the influence of the postinjection protocols on the 
outcomes of PRP injection. From the results of the present study, no relation seems to 
be present between a specific postinjection protocol and the spread of PRP. Hence, 
when extrapolating the results of our study to clinical scenarios, no benefit seems to 
exist for 1 compared with the other postinjection protocol. The clinical use of different 
postinjection protocols therefore remains debatable. Compared with direct dissec-
tion, a substantially more expanded spread of PRP was found with any postinjection 
protocol.6 The direct dissection injections were placed identical to the injections used 
in the present study, with only the postinjection method as the variable. The different 
results are obvious. Wiegerinck et al.6 published a craniocaudal spread of 95 mm directly 
after injection.6 Compared with the current median of 135 mm in the simulated rest 
group and 140 mm in the simulated movement group, substantially expanded spread 
was noted. Although it might seem irrelevant and prone to bias to compare the spread 
of PRP directly after dissection (this was not a clinical situation), with any postinjection 
protocol, the findings were highly interesting. Also, from this comparison, one can 
conclude that PRP will spread further than was observed directly after the injection.6 
Hence, it might not be necessary to locate the PRP exactly at the location of the patho-
logic lesion, knowing the PRP will spread substantially throughout the entire AT (and 
its near surrounding tissue). One of the obvious limitations of the present study was 
the cadaveric setting in which our study was performed. Logically, the effect of blood 
flow, microcirculation, muscle pumps, and diffusion at the cellular level was not possible 
to test in the present study.17,18 However, the results of our study have shown a large 
spread of PRP after injection. The spread seen in the present study would easily reach 
over the preferred designated location of the PRP to treat Achilles tendinopathy. When 
taking the possible beneficial effects of blood flow and muscle pumps into account, 
one can hypothesize that the in vitro spread would be even larger than that in the ca-
daveric setting.17,18 We realize that our conclusions could be threatened by a number of 
methodologic shortcomings. As previously stated, we were not informed about any AT-
related pathologic features of the limbs. However, the fresh frozen limbs were selected 
to not have any macroscopic scarring in the AT region, and no hypoechoic zones were 
observed during the ultrasound-guided injection. Another possible limitation with the 
use of any fresh frozen cadaveric specimens is contracture, specimen age, and method 
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of freezing and defrosting. This was countered by using the hospital’s standard fresh 
frozen limb freezing and prolonged defrosting protocol. After dissection, we did not 
perform any histologic testing of the state of the AT. As mentioned, the results might be 
different in a noncadaveric setting. Also, the total group (power) of the present study 
was low (n ¼ 5 in each group). No proper statistical analyses could be performed with 
such a small group owing to the presence of a type 2 statistical error. A full analysis 
would suggest the proper power of the study, creating an unjustifiable suggestion that 
the results, regardless of their outcome, were based on proper power. The postinjection 
protocols used were chosen in accordance with results from previous clinical studies; 
however, postinjection placement in the patients differed substantially among the stud-
ies. Some have advised supine placement, which was not evaluated in our study; others 
have advised a prolonged prone position. The results of the present cadaveric study 
should not be used to represent these postinjection protocols. Furthermore, because 
these protocols have differed slightly or substantially, the effect of gravity should not 
be underestimated; this was not evaluated in the present study. Finally, the comparison 
with the previous study in this field was prone to bias because methodologic differences 
and interpretation could easily occur.6 Additional evaluation of the spread of PRP could 
be of interest, because all current studies regarding this matter have been cadaveric. 
Future studies should thus focus on the evaluation of the spread of PRP in vivo. In con-
clusion, we found every AT to have been gradually infiltrated with PRP after mid-portion 
AT injection. No difference was found in the craniocaudal spread between 15 minutes 
of rest after injection and 100 manipulations after injection. The plantaris tendon was 
never infiltrated with PRP in either subgroup. Our findings showed no relation between 
the spread of PRP (both intratendinously and peritendinously) and a specific postinjec-
tion protocol after mid-portion AT PRP injection.
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AbstrAct
Neovascularization is frequently observed in tendinopathy. Previous studies have 
focused on the role of neovascularization in Achilles tendinopathy, but have been 
conducted in small series. It is still unclear whether the degree of neovascularization 
is related to severity of symptoms. The purpose was to study the relationship between 
ultrasonographic neovascularization and clinical severity in patients with Achilles tendi-
nopathy. In this prospective cohort study, data on 127 patients (141 tendons) were as-
sembled from databases of three clinical trials. All patients followed an eccentric exercise 
program. The Öhberg neovascularization score (0–4+) and Victorian Institute of Sports 
Assessment-Achilles (VISA-A) score (split into domains: pain, function and activity) were 
collected during baseline and follow-up. The relationship between neovascularization 
and VISA-A score was calculated. At baseline, 107 tendons (76%) showed some degree 
of neovascularization. In 556 coupled measurements, neovascularization was weakly 
related to the VISA-A score [Exp (B) 1.017, 95% confidence interval (CI), 1.007–1.026]. 
No significant relationship was found between neovascularization and the pain domain 
(P = 0.277) and the activity domain (P = 0.283), but there was between neovasculariza-
tion and the function domain of the VISA-A score [Exp (B) = 1.067, 95% CI 1.018–1.119]. 
In conclusion, neovascularization in Achilles tendinopathy is weakly related to clinical 
severity, mainly based on the function domain of the VISA-A score.
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introduction
Although chronic Achilles tendinopathy is common in athletes and the sedentary, the 
exact pathologic mechanism is still unknown. Some suggest a disbalance in loading is 
important, other hypotheses are focused on excessive vessel and nerve ingrowth as a 
cause of the pain. Irrespective of the unknown etiology, Achilles tendinopathy is a clear 
clinical diagnosis based on a combination of pain, swelling, and impaired performance.1
A commonly used method to evaluate the severity of Achilles tendinopathy is the 
Victorian Institute of Sports Assessment-Achilles (VISA-A) questionnaire. This patient-
reported questionnaire provides a valid and reliable index of the clinical severity.2 Like 
other validated questionnaires for musculoskeletal injuries, it covers three domains: 
pain, function, and activity.
The ingrowth of new blood vessels into tendinopathic areas of a tendon can often be 
seen on ultrasound. The assessment of the severity of neovascularization can be done 
reliably using the modified Öhberg scoring system.3,4 Neovascularization, detected 
on the ultrasonographic images using power Doppler or color Doppler, is frequently 
thought to indicate the severity of Achilles tendinopathy.3 It has frequently been hy-
pothesized that neovascularization and the accompanying nerves are the source of pain 
in chronic midportion Achilles tendinopathy.5 However, the results are conflicting and 
not all studies on the role of neovascularization have found this relationship. Some stud-
ies found neovascularization in only 47–88% of the symptomatic cases,6-9 while others 
found neovascularization in all symptomatic tendons.3,10-12 
Only a few studies have examined the relationship between neovascularization and 
pain or function in Achilles tendinopathy. Reiter et al. found a positive relationship 
between the presence of neovascularization and pain and restricted function in 20 
patients,8 but de Vos et al. found no relationship between degree of neovascularization 
and pain or VISA-A score.9 Because of low patient numbers and variation between study 
protocols, the exact role of neovascularization is still unknown.13 
This study had two aims. The first was to investigate the relationship between neo-
vascularization and clinical severity parameter (VISA-A score) in a large database of 
three clinical trials. The second was to find out if baseline characteristics available in 
the databases used for this study, such as age and duration of symptoms influence the 
presence of neovascularization at baseline.
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MAteriAl And Methods
patients
In this cross-sectional study, data from three different clinical trials was used: two ran-
domized controlled trials (RCT) and one observational prospective clinical trial.9,14-19 All 
patients in these studies were clinically diagnosed with Achilles tendinopathy based on 
a painful swelling 2–7 cm proximal to the distal insertion (see Table  1). They were all 
treated with an eccentric training program, as described by Alfredson et al.5 In two trials, 
an additional therapy was studied, the use of a night splint, which provides passive dor-
sal flexion or platelet-rich plasma injection.14-18 The inclusion criteria were similar for all 
of the three studies and are listed in Table 1. Age, gender, height, weight, sports partici-
pation, and duration of symptoms were collected at baseline in all studies. At baseline 
and all follow-up moments the patients were asked to fill in the VISA-A questionnaire 
with minimal researcher assistance. The researcher was present when completing the 
questionnaire and the patient may possibly asked a question, but the researcher did 
not influence the patient. Besides, ultrasound Doppler was performed and evaluated 
during the examination by a blinded observer at baseline and all follow-up moments. 
One study had two follow-up moments: at 12 and 52 weeks.14,15 The other studies16-19 
measured both outcomes at five different times: 6, 12, 24, and 52 weeks, and 2, 8, 16, and 
24 weeks after baseline. All study protocols were approved by regional Medical Ethics 
Committee (MEC05-21, MEC08-041, and MEC05-100).
VisA-A score
The VISA-A questionnaire (0–100) consists of eight questions and provides a standard-
ized measure of severity. The validation and reliability has been tested by Robinson et 
al.2 After a literature research and interviews with patients and experts in the area of 
Achilles tendinopathy, a focus group stated that the questionnaire should include the 
three domains of pain, function in daily living and sporting activity. The pain domain 
(questions1–3), the function domain (questions 4–6) and the activity domain (questions 
7 and 8) contribute equally to the total score. The worst possible score is 0 and the best 
table 1: Inclusion and exclusion criteria
inclusion criteria exclusion criteria
Clinical diagnosis “chronic midportion Achilles tendinopathy”:
Painful swelling 2–7 cm proximal to the distal insertion
Clinical suspicion of other musculoskeletal 
injuries (insertional disorders or ruptures)
Age 18–70 years Systemic illness
 Already performed heavy load eccentric 
exercises or inability to perform the exercises
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possible score is 30 for pain and function domain and 40 for the activity domain. The 
VISA-A questionnaire has a good test–retest reliability (r = 0.93).2
ultrasonographic examination
Neovascularization was determined by Doppler ultrasonography of the Achilles tendon 
in both transversal and longitudinal planes and scored according to Öhberg3 ranged 
from 0 to 4+. The examinations were performed by a musculoskeletal radiologist and 
two trained observers (R. D. V. and S. D. J.). On investigation, the neovascularization score 
was evaluated as 0 (no vessels visible), 1+ (one vessel mostly in the anterior part), 2+ 
(one or two vessels throughout the tendon), 3+ (three vessels through- out the ten-
don), and 4+ (more than three large vessels throughout the tendon). In one study,14,15 
ultrasound measurements at the first two appointments were obtained using a linear 
high-frequency 8–13-MHz transducer with a pulse repetition frequency of 868 Hz 
(Elegra; Siemens Medical Systems, Erlangen, Germany). At the latest follow-up a linear 
high-frequency 12–15-MHz transducer with a pulse repetition frequency of 500–1000 
Hz (MyLab30) was used. Exactly the same device was used in the other two studies.16-18
statistical analysis
Statistical Package for the Social Sciences (SPSS) version 17.0 statistical software (SPSS 
Science Inc., Chicago, IL, USA) was used for the statistical analysis. Associations between 
different baseline parameters and presence of neovascularization at baseline were 
measured using a binary logistic regression model. To determine relationship between 
the presence of neovascularization and VISA-A scores and different domains of VISA-A 
scores a binary logistic regression model was also used. Adjustments were made for 
the variables that influenced the outcome with P  <  0.10. Odds ratios [Exp(B) ] were 
obtained. According to the Cohen’s effect size criteria, an odds ratio of less than 1.50 
was considered to be weak, an odds ratio of 1.50–4.30 was considered to be moder-
ate, and an odds ratio above 4.30 was called strong. To compare different parameters, 
such as increase/decrease in neovascularization on improvement in VISA-A score over 
a short time period, changes in neovascularization and VISA-A score between baseline 
and the first follow-up directly after the 12–16 weeks eccentric exercise program were 
calculated. For the long-term period, changes in neovascularization and VISA-A score 
between baseline and the 1-year follow-up moment of the study were calculated. To cal-
culate the prognostic value of all parameters in the short and longer terms, a repeated 
measurement general linear model was used. Statistical significance was assumed when 
P-values were less than 0.05.
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results
patients
Patients were included in the clinical trials between March 2005 and February 2009. One 
hundred forty-one tendons of 127 patients (57% female) were included. Mean age was 
47.1 years [standard deviation (SD) 8.7] and mean body mass index (BMI) was 25.8 kg/
m2 (SD 3.6). 91% of the patients were active in sports, 41 patients (32%) at competitive 
level and 87 patients (68%) at recreational level. Mean VISA-A score was 49.0 (SD 18.5) 
and the median of the duration of symptoms was 38 weeks (interquartile range 24–88). 
The seven follow-up moments were at different time points ranging from 2 to 52 weeks 
after the baseline measurements (see Table 2). Eight VISA-A scores were missing because 
two patients were lost to follow-up (n = 7) and one patient failed to attend a follow-up 
moment (n = 1). Twenty-five neovascularization scores were lacking because of the two 
patients who were lost to follow-up (n = 7), repair of the sonographic machine (n = 5), 
and patients failing to attend the follow-up moment (n  =  12). A total of 556 cases in 
which both VISA-A and modified Öhberg score were measured were collected in the 
database. In nine patients, the VISA-A questionnaire was not able to split the score into 
the different domains, because the hard copy questionnaires were not available.
neovascularization at baseline
At baseline, 107 tendons (76%) showed some degree of neovascularization, whereas in 
34 tendons (24%) no vascularization was found on Doppler ultrasonography. In a binary 
logistic regression model no significant associations were found between presence of 
neovascularization at baseline and age (P = 0.600), gender (P = 0.958), BMI (P = 0.123), 
sports participation (P = 0.708), and duration of symptoms (P = 0.622). Study type was 
considered as predictor for the primary outcome (P  =  0.035), therefore adjustments 
were made for this parameter in all analyses.
table 2: Overview of number of patients and tendons for each time point
 
time points (weeks)
0 2 6 8 12 16 24 52
Patients 127 25 53 25 102 25 78 102
Tendons 141 25 54 25 116 25 79 116
VISA-A questionnaires 141 24 54 23 116 22 77 116
Doppler analysis 141 23 54 23 111 22 77 105
VISA-A, Victorian Institute of Sports Assessment-Achilles.
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relationship between neovascularization and clinical outcome
All 556 coupled measurements are shown in Figure  1. Tendons without neovessels 
had a mean corresponding VISA-A score of 68.9 (SD 27.3) and tendons with neoves-
sels had a corresponding VISA-A score of 59.1 (SD 23.0). With an Exp(B) of 1.017 (95% 
CI, 1.007–1.026) a statistically significant, but weak relationship between presence of 
neovascularization and VISA-A score was found in a binary logistic regression model 
(P < 0.001). Figure 2 shows the mean scores of the different domains (pain, function, and 
activity) in patients with and without neovascularization. A significant relationship was 
found between the functional domain of the VISA-A score and neovascularization score 
(P = 0.007). However, the regression coefficient Exp(B) of 1.067 (95% CI 1.018–1.119) in-
dicates that the relationship is weak. No statistically significant relationships were found 
between the VISA-A pain domain and neovascularization score (P = 0.277) or between 
the activity domain of the VISA-A score and neovascularization score (P = 0.283).
prognostic value of neovascularization
Short- (12–16-week follow-up) and long-term (1-year follow-up) improvements in 
VISA-A score within groups with (grades 1–4) and without neovascularization (grade 
0) at baseline are shown in Figure 3. In a general linear model, only the baseline VISA-A 
score significantly influenced the short- and long-term improvement in VISA-A score 
(P  <  0.001). A higher VISA-A score at baseline resulted in less improvement in VISA-A 
score. A longer duration of symptoms resulted in less improvement of the VISA-A score 
in the longer term, this influence was significant (P = 0.037).
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figure 1: Individual Victorian Institute of Sports Assessment-Achilles (VISA-A) scores in patients with and 
without neovessels at different time points during the studies. The lines indicate the mean VISA-A scores of 
the groups. Patients without neovessels had a mean VISA-A score of 68.9 and patients with neovessels had 
a mean VISA-A score of 59.1.
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figure 2: Mean Victorian Institute of Sports Assessment-Achilles (VISA-A) scores in patients with some de-
gree of neovascularization (white bars) compared with patients without neovascularization (grey bars) for 
the three different VISA-A domains of pain, function, and activity. Error bars denote standard deviation (SD). 
The functional domain differed significantly between patients with and without neovessels (P = 0.007). No 
statistically significant differences were found for the pain domain and the activity domain of the VISA-A 
score.
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figure 3: Short- and long-term changes in Victorian Institute of Sports Assessment-Achilles (VISA-A) score 
in patients with and without neovessels at baseline. Presence of neovascularization at baseline did not influ-
ence the short-term improvement significantly (P = 0.337) neither the long-term improvement (P = 0.865). 
The last follow-up after eccentric exercise program (EEP) ranged from 24 weeks to 1 year.
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discussion
This is the first study analyzing the clinical significance of neovascularization in Achilles 
tendinopathy in more than 500 paired measurements. Approximately, a quarter of the 
symptomatic patients showed no degree of neovascularization. A weak relationship 
between the neovascularization score and VISA-A score was found. A relationship 
between the VISA-A domain of function could be identified, but not with the VISA-A 
domains of pain and activity. The fact that no relationship with the pain domain (first 
three questions) could be found, seems to contradict with the frequently cited hypoth-
esis that the source of pain in chronic midportion Achilles tendinosis is related to the 
ingrowth of neovessels and accompanying nerves.20 Many studies have been done on 
the presence of neovascularization in tendinopathy, but unfortunately with inadequate 
numbers of patients. Whereas some research groups have reported neovascularization 
in all symptomatic patients ,3,10-12 other study groups have shown that only 47–88% of 
the symptomatic patients had some degree of neovascularization.6-9 For the presence 
of neovascularization in other types of tendinopathy, like patellar tendinopathy and 
plantar fasciitis, even less evidence is available.21-23 A possible reason for the deviations 
in results is the positive effect of activity prior to the measurement on the Doppler flow24 
who showed that neovascularization may be a physical response to activity. However, 
Mahieu et al.25 could not demonstrate this relation in their study, and in another study a 
decrease in neovascularization was found after short activity.26 In the present study the 
patients were not instructed to do or avoid exercises prior to the ultrasound measure-
ment and all measurements were performed at physical rest. It is hypothesized that 
healthy tendons contain physiologically slow blood flow that cannot be detected with 
Power Doppler or Color Doppler techniques, but the threshold for detectable flow in 
tendons is still unknown.23,27 Zanetti et al.7 studied the relationship between clinical 
severity and neovascularization in 40 patients with Achilles tendinopathy and found no 
significant difference in VAS pain score between patients with and without neovascular-
ization. Reiter et al.8 concluded that patients with detected blood flow had a significantly 
lower VISA-A score than those without blood flow. This is in accordance with our finding 
that the VISA-A score was higher in patients without neovessels, although the relation-
ship between VISA-A score and neovascularization score was only weak in our study. 
This weak relationship was mainly based on the relationship between the functional 
domain of the VISA-A score and neovascularization score. No significant relationships 
were found for the pain domain or activity domain of the VISA-A score. Although the 
questionnaire was designed based on these three domains, one may wonder to what 
extent the domains influence each other. In the present study, a decrease in neovas-
cularization did not result in an increase in VISA-A score on either short- and long-term 
outcomes after the treatment. Comparable results have been published by others.7,9 
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Whereas some therapies destroy the neovessels with irritant solutions it is also known 
from the literature that neovascularization is a critical phase in physiological tendon 
healing after trauma.28,29 Power Doppler ultrasonography is unable to distinguish 
between the pathological neovascularization and neovessels necessary in the healing 
response. The strength of this study was the large pooled database, but there were 
also some limitations. Although the inclusion criteria in the three studies we combined 
were more or less the same (see Table 1), there may have been some small differences 
between the study populations. The most important difference may be the fact that the 
patients do not have the same amount of sporting activities. Besides, the additional 
therapies next to the eccentric exercise program differed between the studies. In our 
analyses we therefore corrected for type of study. Additional analyses with adjustments 
for parameters that influenced the primary outcome with P < 0.20 (BMI) did not change 
the conclusions of our study. The study might have lost power by dichotomizing the 
primary outcome (neovascularization); however, because of ordinal scale, it was judged 
that this was a more valid choice than assessing using linear techniques. The methods 
used to examine neovascularization in the studies were either color Doppler ultrasound 
or power Doppler ultrasound, both of which have been shown to be equally effective in 
detecting neovascularization.8 Although different observers scored the degree of neo-
vascularization during the studies, Sengkerij et al.4 reported that the technique used, the 
modified Öhberg scoring system (intraclass correlation coefficient 0.85), has an excel-
lent interobserver reliability for scoring neovascularization in patients with midportion 
Achilles tendinopathy.4
perspectiVes
The absence of either a positive or a negative role of neovascularization in tendinopa-
thy implies there is a discrepancy between imaging and the clinical picture. Although 
neovascularization can be scored very reliably,4 the interpretation of this outcome with 
respect to patient-related outcomes is lacking. This may explain the recently published 
inferior results of sclerosing neovessels22,30 compared with earlier trials.11,12 Our results 
are in line with the current concept that neovessels should not be the only target for 
treatment of Achilles tendinopathy.32,33
conclusion
This study showed that neovascularization was not present in 24% of chronic symp-
tomatic Achilles tendons. A longer duration of symptoms was not related to presence 
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of neovascularization. The weak relationship between neovascularization and clinical 
outcome (VISA-A score) is based on the relationship with the function domain of the 
questionnaire. For the other domains, pain and activity of the VISA-A questionnaire, no 
relationship between neovascularization and the domain was found. A decrease in neo-
vascularization over time during the study was not related with a better improvement 
in the VISA-A score. Based on this study, with over 500 paired measurements, there is no 
relation- ship between the amount of pain and degree of neovascularization. A longer 
duration of symptoms at baseline was associated with less improvement of complaints 
after the treatment.
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AbstrAct
background: Musculotendinous overuse injuries are prevalent in people with type 2 
diabetes. Non-enzymatic glycosylation of collagen resulting in tendon stiffening may 
play a role. In this case–control study we determined whether patients with diabetes had 
poorer ultrasonographic structure in their Achilles tendons compared to age-matched 
controls.
Methods: People with type 1 diabetes or type 2 diabetes, and age-matched controls, had 
computerised ultrasound tissue characterisation of both Achilles tendons. In contiguous 
ultrasonographic images of the tendon, echopatterns were quantified and categorised 
into four echo-types. Tendon abnormality was quantified as sum of echo-types III+IV. 
Furthermore, skin autofluorescence (AF) of the forearm (AF-value) was gathered.
results: Twenty four type 2 diabetes patients, 24 controls, 24 type 1 diabetes patients 
and 20 controls were included. AF-value was higher in type 1 diabetes (1.55±0.17) than 
in their controls (1.39±0.18, p<0.001) and in type 2 diabetes (2.28±0.38) compared to 
their controls (1.84±0.32, p<0.001) Achilles tendons of type 2 diabetes patients con-
tained more echo-types III+IV (14.1±7.9%) than matched controls (8.0±5.4%, p<0.001). 
There was a trend towards a difference in echo-types III+IV between type 1 diabetes pa-
tients (9.5±5.3%) and their controls (6.5±3.7%, p=0.055). In a stepwise linear regression 
analysis, body mass index (BMI) was moderately associated with tendon abnormality in 
patients with diabetes and controls (β=0.393, p<0.001).
conclusions: Type 2, and possibly type 1, diabetes patients showed poorer ultrasono-
graphic Achilles tendon structure that may be a risk factor for tendinopathy. Although 
markers for accumulation of advanced glycation end products were elevated in both 
diabetes populations, only BMI was associated with these abnormalities.
Trial registration number NTR2209.
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introduction
Exercise is a cornerstone in the treatment of type 2 diabetes mellitus. However, patients 
with diabetes are vulnerable to overuse injuries.1-4 Although not significant, diabetes 
seemed more prevalent in people with Achilles tendinopathy than in asymptomatic 
people.5 These injuries may be due to overload because of obesity or altered moving 
patterns due to motor-sensory neuropathy, but tendons might also be directly affected 
by hyperglycaemia.6 Previous research shows that people with type 2 diabetes have 
thicker tendons7–9 and an increased level of ultrasonographic tendon disorganisa-
tion.10–12 Craig et al.13 reported an association between plantar fascia thickness and 
complications in type 1 diabetes. Unfortunately, these studies were hampered by the 
fact that standard two-dimensional ultrasonography does not quantify tendon struc-
ture. Although Movinetal14 showed that hypoechoic areas seen on ultrasonography 
corresponded to histological collagen degeneration, a recent rodent study indicated 
that experimental induced diabetes resulted in structural, inflammatory and vascular 
changes in the Achilles tendon.15 Hyperglycaemia itself may also increase expression 
of matrix metalloproteinase-9 and metalloproteinase-13 in tendon cells and impair 
collagen synthesis.16 Nevertheless, the pathomechanics behind tendon degeneration in 
either type 1 or type 2 diabetes is most likely multifactorial and still largely unknown.12,17 
It can be hypothesised that the accumulation of non-enzymatic advanced glycation 
end products (AGEs) in the connective tissues cause tendon overuse injuries and in-
creased matrix disorganisation.18 AGEs are the result of non-enzymatic glycosylation 
of proteins, induced by diabetes-related hyperglycaemia and hyperlipidaemia. AGEs 
create cross-links with short and long-lived proteins, and the formation of AGEs is one of 
the pathophysiological mechanisms that links hyperglycaemia and hyperlipidaemia to 
microvascular and macrovascular pathology. Since AGEs also form cross-links with colla-
gen they might explain the predisposition to tendinopathy in people with diabetes.19 An 
autopsy study showed significantly higher levels of non-enzymatically bound glucose in 
tendons and other tissues of patients with type 2 diabetes.20 A validated non-invasive 
technique to estimate the level of glycated collagen in the skin is autofluorescence (AF).21 
AGE levels based on skin biopsies22 and the skin AF measurement have been shown to 
be independent predictors for both the severity of long-term hyperglycaemia as well 
as the development of microvascular23 and macrovascular22 complications and cardiac 
death in type 1 diabetes and type 2 diabetes.24 Ultrasound tissue characterisation (UTC) 
was developed in equine tendons to detect and quantify more subtle tendon structural 
changes.25,26 In contiguous ultrasonographic images, dedicated algorithms quantified 
three-dimensional (3D)-stability of echo-patterns. Four echo-types can be discriminated: 
(I) intact and aligned tendon bundles; (II) discontinuous or waving tendon bundles; (III) 
fibrillar tissue; (IV) amorphous tissue with mainly cellular components and fluid. Greater 
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levels of echo-types III+IV suggest poorer tendon structure. In previous human research 
symptomatic tendons showed significantly more echo-types III+IV than asymptomatic 
tendons.27 The primary aim of this study was to compare Achilles tendon structure in 
type 1 diabetes and type 2 diabetes patients with healthy age-matched controls. The 
secondary study aim was to correlate skin AF as a general indicator of AGEs with Achilles 
tendon structure. Furthermore, we investigated if age, body mass index (BMI), duration 
of diabetes, sports activity and glycated haemoglobin (HbA1c) levels were associated 
with Achilles tendon structure.
Methods
patients
Patients and age-matched control participants were recruited in outpatient depart-
ments at the Erasmus MC University Medical Center in Rotterdam, The Netherlands, and 
a national expert centre for diabetes care (Diabeter, Rotterdam, the Netherlands). Inclu-
sion criteria for the case group were type 1 diabetes (aged between 18 and 30 years) 
or type 2 diabetes (aged 35–60 years) diagnosed according to the WHO criteria. People 
with Achilles tendon pain and participants whose ultrasound scan was of poor quality 
were excluded. A written informed consent was obtained from all participants before 
participation in the study, approved by the ethical committee of the Erasmus University 
Medical Center in Rotterdam and listed in the Dutch Trial Register (number NTR2209).
study measurements
Weight and height were measured to calculate the BMI. All participants recorded current 
sports and exercise activities (hours/week). Fasting venous blood samples were collected 
in a sodium fluoride tube and EDTA tube to, respectively, measure fasting glucose by a 
clinical chemistry analyser (Modular P Module, Roche Diagnostics, Almere, the Neth-
erlands) and blood HbA1c content through high-performance liquid chromatography 
(ADAMS A1c HA-8160 analyser, Arkray Europe B.V., Amstelveen, the Netherlands).
Activity monitor
The participants received a preprogrammed accelerometer (GT1M; ActiGraph, LLC, Pen-
sacola, Florida, USA) and wore it on the right hip for seven consecutive days while awake 
and not in the water. The activity levels assessed by the accelerometer are presented as 
mean counts per day.
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skin Af
Forearm skin AF was measured using the AGE-Reader (DiagnOptics Technologies BV, 
Groningen, the Netherlands). The AGE-Reader is a desktop device that uses the char-
acteristic fluorescent properties of glycated collagen to estimate the level of AGE ac-
cumulation in the skin.24 The measurement is automated and obtained by placing the 
forearm on the device. Three measurements were taken and the mean AF-score of the 
three measurements was used in the analyses.
ultrasound tissue characterisation
Tendon integrity was evaluated quantitatively by one of two experienced examiners 
(HTMvS and SdJ) with the use of UTC (UTC2000, UTC imaging, Stein, the Netherlands). 
Participants were laying prone on an examination table  with their feet hanging over 
the edge and with the ankle in approximately 5–10° dorsiflexion, to slightly pretension 
the Achilles tendon. A 10MHz linear-array transducer (Smartprobe 10L5, Terason 2000, 
Teratech, USA) was moved automatically along and perpendicular to the Achilles ten-
don’s long axis by means of a motor-drive. Transverse images were collected at regular 
distances of 0.2 mm and a 3D data block was reconstructed. The following UTC setting 
was used; Window Size=9. The stability of the echo pattern over contiguous images 
was analysed by means of custom-designed algorithms (UTC 2010 UTC imaging, http://
www.utcimaging.com) resulting in discrimination of four echo-types. Previous research 
has shown that these echotypes are highly correlated to histomorphology of tendon 
tissue at various stages of integrity. Echotypes I and II represent more or less organised 
(secondary) tendon bundles. Echotypes III represent smaller, disorganised and more 
fibrillar tissue. Echotypes IV represent amorphous tissue.27 By one blinded researcher 
(SdJ), a point 4 cm from calcaneal insertion was determined in the sagittal plane. The 
tendon border was outlined at five equally spaced points from 3 to 5 cm proximal to 
the calcaneal insertion. The five outlines were interpolated to create a tendon volume 
of 2 cm length, making the region of interest for analysis. Proportions of the four echo-
types were calculated within this volume. The sum of echo-types III and IV, representing 
poorer tendon structure, was used for statistical analyses. The interobserver reliability of 
this method appeared to be excellent with an intraclass correlation coefficient (ICC) of 
0.89 and a mean difference of 0.9% in the sum of echo-types III+IV.28
statistical analysis
Statistical analyses were performed using statistical software (PASW V.19.0). Values 
are presented as mean±SD for normally distributed parameters. For non-parametric 
parameters median and IQR are given. Differences in echo-types III+IV, AGE value and 
non-parametric baseline characteristics between the groups were tested using the 
Mann-Whitney U test. For differences in parametric baseline characteristics the unpaired 
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t test was used. To calculate the association between the parameters age, BMI, AF-score, 
duration of diabetes, hours of sports participation, blood HbA1c level and tendon struc-
ture, a stepwise linear regression analysis was used. Standardised regression coefficients 
(β) were given. A p<0.05 level was chosen to indicate statistical significance.
results
Sixty two people with diabetes and 58 age-matched controls were screened for eligibil-
ity and resulted in 102 participants who met the inclusion criteria (figure 1). Ten people 
were excluded because of abnormal blood results (n=3), presence of Achilles tendon 
pain (n=3) or technical failure of ultrasound (n=4). Those with type 2 diabetes had a 
significantly higher BMI than their controls (table 1). Fewer people with type 1 diabetes 
were active in sports (75%), compared to their controls (95%). The self-reported hours 
of sport participation was significantly higher in the controls compared to the patients 
with diabetes.
skin Af measurement
Mean AF-score for the type 1 diabetes group was 1.54 (0.16), which is 111% (12.0) of the 
predicted value for equally aged healthy individuals using the Koetsier et al.21 regres-
sion model. The control group for type 1 diabetes had a mean AF-score of 1.38 (0.19): 
98% (13.8) of predicted value. This was significantly lower than the patients with type 1 
table 1: Baseline characteristics
 
type 1 
diabetes controls
p Value
type 2 
diabetes controls
p Valuen=24 n=20 n=24 n=24
Age (years) mean (SD) 23.3 (3.2) 24.2 (2.7) 0.386 49.6 (7.9) 46.6 (6.0) 0.114
Gender (% male) 37.5 45.0 0.760 62.5 54.2 0.770
Duration of diabetes (years) median (IQR) 12 (18) NA 6.8 (7.5) NA
BMI (kg/m2) mean (SD) 24.6 (2.8) 23.3 (2.6) 0.124 31.7 (5.0) 26.4 (4.5) <0.001
HbA1c (mmol/mol) median (IQR) 59.5 (11) 32.5 (2) <0.001 50 (16) 35 (5) <0.001
Hours sports/week* median (IQR) 2.5 (4) 5 (8) 0.018 1 (3) 3 (4) 0.029
PA (×106 counts/day)† median (IQR) 1.47 (0.84) 1.84 (0.99) 0.133 1.68 (1.47) 2.01 (1.52) 0.218
AF-score (AU)‡ mean (SD) 1.54 (0.16) 1.38 (0.19) 0.008 2.31 (0.40) 1.85 0.31) <0.001
*Hours sports/week: self-reported estimate of weekly hours participating in sports activities. †PA: objec-
tively determined physical activity level (in counts per day) based on seven-day activity monitoring. ‡AF-
score: average skin autofluorescence score based on three AGE-reader measurements of forearm. AGE, 
advanced glycation end products; AF, autofluorescence; AU, arbitrary units; BMI, body mass index; HbA1c, 
glycated haemoglobin; PA, physical activity.
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diabetes (p=0.008). The AF score of the type 2 diabetes patients was 2.31 (0.40), 114% 
(16.8) of the predicted value for healthy individuals. Their controls had significant lower 
value of 1.85 (0.31), which is 95% (16.1) of predicted value, p<0.001).
ultrasound tissue characterisation
Tendons of people with type 1 diabetes contained 9.5% (5.3) echo-types III+IV (table 2). 
The tendons of matched controls contained 6.5% (3.7) echo-types III+IV (p=0.055). 
People with type 2 diabetes and matched controls had, respectively, 14.1% (7.9) and 
8.0% (5.4) echo-types III+IV (p<0.001). In a stepwise multiple regression analysis BMI 
(β=0.393, p<0.001) and presence of diabetes (β=0.234, p=0.024) was associated with 
poorer tendon structure (echo-types III+IV). HbA1c (β=0.095, p=0.549), age (β=0.070, 
p=0.516), hours of sports participation (β=0.047, p=0.653) and AF score (β=0.003, 
p=0.978) did not contribute significantly to the model. In a subanalysis on the predictive 
value of diabetes-associated parameters in the patients with diabetes, only BMI was 
associated with Achilles tendon structure. Duration of diabetes (β=−0.013, p=0.933), 
HbA1c (β=−0.055, p=0.715) and AF score (β=0.075, p=0.683) did not contribute to the 
regression model.
discussion
This study shows that asymptomatic Achilles tendons of people with type 2 diabetes 
had worse structure than age-matched controls. The observed difference in tendon 
disorganisation between type 1 diabetes patients and healthy matched controls did 
not reach statistical significance and requires replication. Nevertheless, it is an interest-
ing finding that can be regarded as a hint that the hyperglycaemic state in young, but 
otherwise healthy, type 1 diabetes patients may lead to an impaired Achilles tendon 
structure. These ultrasonographic tendon structure irregularities suggest tendon disin-
tegration, which may lead to clinical symptoms of tendinopathy.25-27 This finding might 
explain previous study results showing tendinomuscular overuse injury as a frequent 
table 2: Mean proportions of four echo-types measured with UTC
 
type 1 diabetes controls
p Value
type 2 diabetes controls
p Valuen=24 n=20 n=24 n=24
Echo-type I 65.0 (6.9) 68.9 (5.4) 0.032 64.0 (6.4) 76.4 (7.8) 0.018
Echo-type II 25.6 (3.3) 24.8 (3.1) 0.408 22.1 (4.0) 24.6 (4.2) 0.081
Echo-type III 6.1 (3.7) 4.1 (2.3) 0.058 7.0 (3.6) 4.9 (3.9) 0.012
Echo-type IV 3.4 (1.7) 2.4 (1.6) 0.058 7.1 (4.6) 3.0 (1.8) 0.001
Echo-types III+IV* 9.5 (5.3) 6.5 (3.7) 0.055 14.1 (7.9) 8.0 (5.4) <0.001
*Echotypes III and IV represent poorer tendon structure. UTC, ultrasound tissue characterisation.
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cause for early termination of exercise programmes in type 2 diabetes.29,30 In accordance, 
our study results extend on a recent qualitative ultrasound study by Abate et al.12 and 
are consistent with epidemiological data providing a hint that diabetes mellitus is more 
prevalent in patients with Achilles tendinopathy than in asymptomatic persons.5 We are 
not sure whether the ultrasonographic differences between diabetes and control groups 
are caused by measurement errors. Nevertheless, our cross-sectional comparison sug-
gests that overweight and obese patients with diabetes participating in weightbearing 
exercise, should be controlled regularly on Achilles tendon pain or stiffness to avoid 
premature drop-out due to Achilles tendinopathy. Since we only measured asymptom-
atic people, we can only speculate at which level of echo-type III and IV asymptomatic 
people with type 1 or type 2 diabetes may develop or experience tendon pain or stiff-
ness. Furthermore, the observed difference in echo-types III+IV between people with 
type 1 diabetes and their aged-matched controls was only borderline significant. Owing 
to limited power, a type 2 statistical error cannot be excluded. Therefore, our findings in 
people with type 1 diabetes should be taken cautiously and warrant further investiga-
tions. 
At this stage, we can only speculate on the underlying causal relation between 
diabetes and the observed ultrasonographic tendon irregularities in our asymptomatic 
populations. In the present study, BMI shows the strongest association with poorer ul-
trasonographic tendon structure (echo-types III+IV). The group with patients with type 
1 diabetes had a mean BMI in the healthy 20–25 kg/m2 range. This may partly explain 
the borderline association with an increased percentage of ultrasonographic tendon 
abnormalities, as BMI has been shown to be an important risk factor for tendinopathy in 
Meeting inclusion criteria
(n=25)
Excluded (n=1)
1 Complaints Achilles tendons
Analysed 
(n=24)
Meeting inclusion criteria
(n=21)
Excluded (n=1)
1 Abnormal blood results
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(n=20)
Meeting inclusion criteria
(n=27)
Excluded (n=3)
1 Complaints Achilles tendons
2 Technical failure ultrasound
Analysed 
(n=24)
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(n=29)
Excluded (n=5)
1 Complaints Achilles tendons
2 Technical failure ultrasound
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Analysed 
(n=24)
Assessed for eligibility
(n=30)
Assessed for eligibility
(n=25)
Assessed for eligibility
(n=32)
Assessed for eligibility
(n=43)
Not meeting inclusion criteria (n=5)
5 Age above inclusion criterion
Not meeting inclusion criteria (n=5)
5 Age above inclusion criterion
Not meeting inclusion criteria (n=4)
4 No blood results available
Not meeting inclusion criteria (n=14)
14 No blood results available
Diabetes type 1 patients Controls for diabetes type 1 patients
Diabetes type 2 patients Controls for diabetes type 2 patients
figure 1: Flow chart.
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previous research.31 However, its association with ultrasonographic tendon disintegra-
tion was not examined previously. The deleterious effect of BMI on tendon disintegra-
tion could be mediated by increased mechanical loading, suggesting that not only body 
weight, but also increased physical activity might be associated with ultrasonographic 
tendon abnormalities. However, our results could not confirm an association or interac-
tion between objectively determined physical activity level, body weight and ultraso-
nographic tendon structure irregularities. In a previous publication, Gaida et al.32 have 
suggested that cytokines released by visceral fat may play a role in the pathogenesis 
of tendinopathy. In addition, they noted that a large proportion of their tendinopathy 
population have signs of metabolic obesity with a normal weight.32 Since we excluded 
participants with clinical tendinopathy, the present study design is not well suited to 
study the long-term effects of metabolic syndrome on Achilles tendon complaints. 
Nevertheless, our results do support the notion that biomarkers for hyperlipidaemia, 
insulin resistance and visceral fat deposition should be integrated in future studies on 
diabetes and tendinopathy risk.31 
Although presence of diabetes was associated with poorer tendon structure on 
ultrasound, diabetes associated parameters, like duration of diabetes, HbA1c and skin 
AF, lack to clarify an association with percentage of ultrasonographic tendon abnor-
malities. Hyperglycaemia could be a determinant for ultrasonographic tendon structure 
abnormalities, but our study does not support the hypothesis that skin AF predicts 
tendon disintegration.33,34 The lack of a significant association does not exclude a role 
of AGEs in tendon pathology, since skin AF has not been validated as a predictor of AGE 
accumulation in the tendon. Skin AF is an indicator of general glycation products and 
known to predict the severity of long-term hyperglycaemia in diabetes. 22,23 The higher 
levels of non-enzymatically bound glucose found in tendons of patients with diabetes 
in an autopsy study20 suggest there is a missing link between skin measured AGEs and 
AGEs in tendons. Different ex vivo studies demonstrated that elevated glycation caused 
increased tendon stiffness.35,36 Possibly this is caused by supraphysiological concentra-
tions of AGE forming metabolites such as methylglyoxal and ribose. Also, other factors 
like pentosidine concentration or altered gait might play a role. Abate et al.17 concluded 
in their review that many complex pathogenetic mechanisms are involved in rheumato-
logical manifestations of diabetes.
One limitation to this study was that, in terms of BMI, our diabetes patients were not 
perfectly matched with the controls. It was particularly difficult to find controls for type 2 
diabetes patients with an equal BMI. Possibly the metabolic syndrome is a risk factor on 
itself and should not be split up. Type 1 diabetes patients were recruited from a national 
expert centre for diabetes care and can be considered a random sample. We cannot be 
certain that the type 2 diabetes patients represent a random sample. Although patients 
were referred by general practitioners and medical specialists and presence of diabetes 
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related diseases was comparable with the prevalence in diabetes type 2 patients in the 
Netherlands, patients were not specifically tested for diabetic polyneuropathy. Never-
theless, clinical polyneuropathy was documented in none of the available medical files 
and was also not reported by the patients. 
This study noticed that people with type 2 diabetes have poorer tendon structure 
measured with ultrasound which may make them vulnerable for tendon overuse inju-
ries. For a good outcome of exercise programmes it is necessary to reduce the risk of 
myotendinous overuse injuries in patients with type 2 diabetes. It might be advisable 
to implement an adapted exercise protocol for the patients at risk for tendinopathy.29 
However, more research is needed to identify these risk factors.
conclusion
This study showed that people with type 2, and potentially also type 1 diabetes, have 
compromised structure of the mid-portion of the Achilles tendon. Although diabetes 
patients have elevated AGE skin AF scores compared with their controls, the difference 
in ultrasonographic tendon disintegration seems to be based mainly on the BMI.
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AbstrAct
objective: The study examined whether the addition of a night splint to eccentric exer-
cises is beneficial for functional outcome in chronic midportion Achilles tendinopathy.
design: One-year follow-up of a randomised controlled single blinded clinical trial.
setting: Sports medicine department in a general hospital.
patients: 58 patients (70 tendons) were included.
interventions: All patients completed a 12-week heavy load eccentric training pro-
gramme. One group received a night splint in addition to eccentric exercises.
Main outcome measurements: Outcome scores were: Victorian Institute of Sport 
Assessment-Achilles (VISA- A) score, subjective patient satisfaction and neovascularisa-
tion score measured with power Doppler ultrasonography (PDU).
results: For both groups the VISA-A score increased significantly (from 50 to 76 (p<0.01) 
in the eccentric group and from 49 to 78 (p<0.01) in the night splint group). No signifi-
cant differences in the VISA-A score were found between the groups from baseline to 
one year (p = 0.32). The presence of neovessels at baseline did not predict a change in 
the VISA-A score after one year in the whole group (p = 0.71).
conclusion: Eccentric exercises with or without a night splint improved functional out-
come at one year follow-up. At follow-up there was no significant difference in clinical 
outcome when a night splint was used in addition to an eccentric exercise programme. 
Between 3 months and one year follow-up, a continuing increase in the VISA-A score 
was found. Assessment of the neovascularisation score with PDU at baseline has no 
prognostic value on long-term clinical outcome.
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.1
introduction
Achilles tendinopathy is the clinical term used when the triad of a painful, swollen 
tendon with impaired function is present.1 Achilles tendinopathy remains a serious 
injury for athletes, especially in running sports.1 Several Scandinavian studies have re-
ported good results with eccentric exercises in the treatment of Achilles tendinopathy.2-4 
Subsequently other studies showed only moderate results.5,6 More recently, a system-
atic review concluded that treatment with eccentric exercises possibly has no benefits 
compared with other forms of exercises.7 Morning stiffness is a common complaint in 
athletes with Achilles tendinopathy.8,9 It was hypothesised that a night splint would be 
effective in reducing morning stiffness. Functional status and return to sports activity 
were not reported in many previous studies. In a systematic review Kingma et al.10 stated 
that, besides pain, the functional outcome should be scored. The authors proposed to 
use the Victorian Institute of Sports Assessment-Achilles (VISA-A) score, which measures 
two factors: pain and physical activity.11 Several studies have used the VISA-A to assess 
outcome.6,12-15 In Achilles tendinopathy, colour and power Doppler ultrasonography 
(PDU) shows an increased vascularity with an increased number of blood vessels, which 
is referred to as ‘‘neovascularisation’’ in the literature.16 The pathophysiological mecha-
nism of these neovessels is unknown.17 Several authors studied the presence of neovas-
cularisation as a prognostic factor for the outcome of treatment of tendinopathy.18,19 The 
first aim of this single blinded prospective randomised trial was to compare the effects 
at one-year follow-up of a heavy load eccentric exercise programme compared with a 
heavy load eccentric programme in combination with the use of a night splint. The sec-
ond aim was to evaluate the change in neovascularisation score at one year follow-up.
MAteriAl And Methods
This is a follow-up study of the randomised controlled trial that initially investigated 
the value of additional splinting to eccentric exercises with use of the VISA-A score and 
PDU.5,18
patients
Patients were referred by a general practitioner, physical therapist or a medical special-
ist. Volunteers without referral were also allowed for inclusion. Inclusion and exclusion 
criteria are summarised in table  1. The diagnosis was established based upon clinical 
examination. When there was pain on palpation of the Achilles tendon, 2–7 cm proximal 
from the distal insertion, the diagnosis of midportion Achilles tendinopathy was made. 
If there was pain on palpation of the insertion, this was considered an insertional ten-
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dinopathy and the patient was excluded. After informed consent was given all patients 
were included by a clinician and then examined by a single researcher. The study proto-
col was approved by the Medical Ethics Committee of the Hospital.
Standardised outcome measures were assessed: The VISA-A score was the primary 
outcome measurement to evaluate the results at follow-up. The VISA-A questionnaire 
was completed with minimal researcher assistance. The first question in VISA-A is re-
lated to morning stiffness (0 to 10). A higher score is associated with less duration of 
stiffness in the morning. Subjective patient satisfaction was scored as excellent, good, 
moderate or poor. PDU was performed and neovascularization was scored according to 
the modified Öhberg score.18 A detailed exercise instruction was performed. Patients 
were randomly assigned into one of the treatment groups, using sealed envelopes. The 
researcher was blinded to this randomisation and patients were instructed not to inform 
the researcher. Patients who were randomly assigned to the night splint group received 
further instruction from their treating physician.
Both groups performed treatment for 12 weeks. The detailed description of the 
treatment has been described earlier.5 Outcome was evaluated by a blinded researcher 
at baseline, 3 months and one year. When patients needed surgery, the outcome was 
considered as poor patient satisfaction, the presurgical VISA-A score was obtained and 
the value used for the final measurement.
ultrasound examination
On the first appointment Doppler ultrasonography was performed using a linear high 
frequency 8–13 MHz transducer with a pulse repetition frequency of 868 Hz. (Elegra; 
Siemens Medical Systems, Erlangen, Germany). At the one-year follow- up a linear high 
frequency 12–15 MHz transducer with a pulse repetition frequency of 500–1000 Hz 
(MyLab30; Esaote Piemedical, Maastricht, The Netherlands) was used. Patients lay prone 
during the examination, with their feet hanging over the edge of the examination table. 
The symptomatic Achilles tendons were observed in the longitudinal and transverse 
plane. On investigation, the researcher and the radiologists scored the neovascularisa-
tion of both Achilles tendons. This score was evaluated as 0 (no vessels visible), 1+ (one 
table 1: Inclusion and exclusion criteria 
inclusion criteria exclusion criteria
Age 18–70 years Insertional disorder
>2 Months’ duration of symptoms Tendon ruptures
Active sport participation before onset Systemic illness
Wish to return to original sports level Heavy load training in the past
Swollen tendon, tender on palpation and during sports Inability to perform exercises
Tendon thickening 2–7 cm proximal to insertion
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vessel mostly in the anterior part), 2+ (one or two vessels throughout the tendon), 3+ 
(three vessels throughout the tendon) and 4+ (more than three large vessels throughout 
the tendon).
Statistical analysis was performed using statistical package for the social sciences 
software (SPSS 12.0). To assess changes over time in the variables within groups the 
Wilcoxon signed rank test was used. The Mann–Whitney U test was used to detect 
changes over time between the two groups. The X2 test was used to evaluate differ-
ences in subjective patient satisfaction between the groups. Statistical significance was 
assumed when p values were less than 0.05. We calculated that the number of subjects 
to treat was 26 for each group. This sample size accounted for a 10% loss to follow-up, 
a significance level of 0.05 and a power of 80%. The assumptions of a delta of 10 points 
on the VISA-A questionnaire and a standard deviation of 12 were based on the data of 
previous studies.11,14
results
patients
At baseline, 70 tendons of 58 patients met the inclusion criteria. Seventy tendons were 
randomly assigned into two treatment groups: 34 in the eccentric group and 36 in the 
night splint group. The mean age was 44.6 years (26–59), the mean body mass index was 
25.1 kg/m2 (20.2–34.5). The mean duration of symptoms was 30.7 months (median 44, 
range 2–204). There were no significant differences in patient characteristics between 
the groups at baseline.
Fifty patients (63 tendons) could be included for follow-up at one year. One patient 
did not answer repeated phone calls and 10 patients were not able to visit our centre 
for PDU examination but did complete the VISA-A scores and patient satisfaction (fig 1).
Between 3 months and one year follow-up, six patients (seven tendons) did not re-
spond to conservative treatment. All had a poor/moderate patient satisfaction score at 
12 weeks follow-up. These patients underwent surgical treatment after a mean duration 
of 9 months (6–12). In these patients, the presurgical VISA-A scores were obtained.
eccentric training
Some patients continued the eccentric exercises at a lower level after the 12 weeks exer-
cise programme. Eleven patients (14 tendons; 22.6%) continued for 1–6 months (mean 
2.5 months). Eight patients (nine tendons; 14.5%) were still doing the exercises at the 
one year follow-up.
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VisA-A score
The VISA-A score in the eccentric group increased significantly from 50.1 at baseline to 
75.7 after one year (p,0.01). From 3 months to one year the VISA-A score also increased 
significantly from 68.8 to 75.7 in the eccentric group (p = 0.02). In the night splint group 
the VISA-A score increased from 49.2 at baseline to 78.2 at one year (p<0.01; fig 2). A 
significant increase was also seen from 3 months follow-up (65.9 points) to one year 
follow-up (p<0.01).
      
 
 
 
 
 
 
 
Assessed for eligibility  (n=79) 
Excluded  (n= 9  ) 
Reasons: 
Insertional disorder (n=4) 
Already performed eccentric 
exercises (n=2) 
Partial rupture (n=1) 
Total rupture (n=1) 
Unable to accomplish eccentric 
exercises (n=1) 
Lost to follow-up  (n= 0   ) 
    
Allocated to Eccentric group  
(n= 34) 
Received allocated intervention  
(n= 32) 
 
Did not receive allocated 
intervention (n= 2) 
Reasons:  
Experienced too much pain (n=1) 
Subluxation peroneal tendons (n=1) 
 
 
Lost to follow-up  (n=3) 
Reasons: 
 Failed to attend (n=2) 
 Left to live overseas 
 
Allocated to Night splint group 
(n=  36) 
Received allocated intervention 
(n=  34) 
 
Did not receive allocated 
intervention (n= 2) 
Reasons: 
 Sleep disturbances (n=2) 
Allocation 
Follow-Up 
One year 
Enrollment 
Randomisation 
Lost to follow-up  (n=0    ) 
    
 
 
Lost to follow-up for PDU (n=4) 
Reasons: 
 Failed t attend (n=4) 
Lost to follow-up  (n=1    ) 
Reasons: 
Didn  
(n=1) 
Lost to follow-up for PDU (n=6) 
Reasons: 
 Failed to attend (n=6) 
Follow-Up 
Three months 
figure 1: Flowchart of patients in the study.
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There was no significant difference found in increases in VISA-A scores between both 
groups from baseline to one year (p = 0.36) and from 3 months to one year (p = 0.24; 
fig 2)
The score for morning stiffness increased significantly in the eccentric group from 5.8 
at baseline to 9.1 at one year follow-up (p<0.01). In the night splint group the score for 
morning stiffness increased significantly from 4.7 at baseline to 8.7 at one-year follow-up 
(p<0.01). There was no significant difference in morning stiffness between both groups 
at baseline (p = 0.19), 3 months follow-up (p = 0.09) and one year follow- up (p = 0.12).
subjective patient satisfaction
As described in table  2, patient satisfaction at one year follow- up in the eccentric 
group was excellent or good in 17 (53.1%) tendons and moderate or poor in 15 (46.9%) 
tendons. After one year the patient satisfaction in the night splint group was excellent 
or good in 21 (70%) tendons and moderate or poor in nine (30%). No significant differ-
ence in patient satisfaction was found between the eccentric group and the night splint 
group (p = 0.20).
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figure 2: Changes in the Victorian Institute of Sports Assessment– Achilles (VISA-A) score in both treatment 
groups at baseline, 3 months follow-up and one year follow-up. No significant differences were found be-
tween the two treatment groups. A significant increase for the eccentric and night splint group between 3 
months and one year follow-up was found.
table 2: Subjective patient satisfaction in both treatment groups at one year follow-up
patient satisfaction
Moderate or poor (%) excellent or good (%)
Eccentric group 15 (47) 17 (53)
Night splint group 9 (30) 21 (70)
The number of tendons is denoted (%). There was no significant difference in patient satisfaction between 
the eccentric group and the night splint group.
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ultrasonographic neovascularisation
At baseline 40 (65%) of the 62 tendons showed some degree of neovascularisation. 
At one year 37 of 52 (71%) showed some degree of neovascularisation. Patients with 
neovessels at baseline (grades 1–4) showed a mean increase in the VISA-A score of 25.7 
from baseline to one year follow-up. Patients without neovessels (grade 0) at baseline 
showed a mean increase of 30.1 in the VISA-A score. There was no significant difference 
in outcome measured with the VISA-A between patients with or without neovessels at 
baseline (p = 0.71; fig 3)
discussion
This randomised trial shows that at one year follow-up there was no difference in 
functional outcome between treatment with eccentric exercise only or a combination 
of eccentric exercises and the use of a night splint in chronic Achilles tendinopathy. The 
improvement in the VISA-A score continued after finishing the 12 weeks of therapy. The 
presence or absence of neovascularisation within or around the Achilles tendon could 
not predict outcome at long-term follow-up.
All studies that compared short-term versus middle and long- term outcomes, showed 
an improvement in the results between 6–12 weeks and one year.9 ,12,20 It is questionable 
if the improvement after a period of 3 months eccentric training is caused by continuing 
the eccentric exercises after the prescribed 3-month period. In our population almost 
a quarter continued the eccentric exercises for 2.5 months on average after finishing 
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figure 3: Changes in the Victorian Institute of Sports Assessment– Achilles (VISA-A) score at baseline, 3 
months and one year follow-up in patients with neovessels (grades 1–4) at baseline and without neovessels 
at baseline (grade 0). There was no significant difference in improvement in the VISA-A score between these 
groups at 3 months and one year follow-up.
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the therapy programme. At one year follow-up 15% were still performing the eccentric 
exercises. This phenomenon has not been reported in previous studies.
Another explanation is the ‘‘slow’’ natural healing process of the tendon. The effect of 
natural healing examined with a wait and see policy, was recently studied by Rompe et 
al.14 They reported that an increase in the VISA-A score from 48 to 55 was found after 4 
months without treatment. This improvement was not statistically significant. Another 
hypothesis is that eccentric exercises elicit longer term adaptations in extracellular matrix 
production. Tendons can adapt to enhanced loading conditions by changing tenocyte 
metabolism, leading to an alteration of structure and composition; however, the process 
of tissue degradation, and the synthesis and incorporation of new matrix components as 
well as the final crosslinking of the newly produced collagen network takes time. Altered 
biomechanical loading conditions can influence tendon cell (tenocyte) metabolic activi-
ties, altering the production and degradation of extracellular matrix components.21 In 
humans it has been demonstrated using a microdialysis technique that collagen type I 
synthesis is increased after 12 weeks eccentric loading of initially injured human Achilles 
tendons.22 From veterinary medicine we know that the tendon repair process in equine 
superficial digital flexors including the final remodelling phase takes many months.23 
Therefore, it is likely that the remodelling of the tendon tissue will continue for a longer 
period even after ceasing the eccentric loading regime. Ultimately this might lead to 
tendon structure adaptation and improved tendon function at long term.24
It may also be that patients might notice an initial relief and symptomatic recovery, 
which frequently precedes a functional recovery. It has been described that an initial 
symptomatic recovery reached shortly after the eccentric exercises does not automati-
cally lead to a long-term functional recovery.25 A postponed or extended period of res-
toration of tendon tissue structure and function might be responsible for the continuing 
increase in the VISA-A score after the eccentric exercises.
Few studies reported the functional results of more than one year follow-up. In a 
study in non-athletes with a mean follow- up of 15 months, Sayana and Maffulli6 have 
shown the VISA-A scores of 34 patients after a 12-week heavy load eccentric exercise 
programme. In their population a significant increase in the VISA-A score from 39 to 50 
was found, which was a smaller improvement than in this study. A possible explanation 
is the difference in the study population. In the study of Sayana and Maffulli6 the patients 
were non-athletes, whereas in this study the included patients were all participating in 
sports. It could be postulated that active individuals do have a better compliance for the 
prescribed exercises. The VISA-A scores after one year in the study of Brown et al.12 are 
more comparable with the present study. Those authors showed an improvement from 
62 to 95 in 18 patients treated with eccentric exercises plus an injection of aprotinin 
or placebo. Other studies also showed an increase in VISA-A scores after finishing the 
eccentric programme.5,14,15
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In contrast to the hypothesis that a night splint would reduce morning stiffness, the 
results in the present study did not show a significant benefit of using a night splint for 
the duration of stiffness in the morning.
There is conflicting evidence on the significance of neovascularisation in Achilles 
tendinopathy.26 Peers et al.27 found a correlation between neovascularisation and pain 
scores and Reiter et al.28 reported a relationship between the presence of neovasculari-
sation and a worse VISA-A score. However, these data were not supported by Zanetti et 
al.,19 and de Vos et al.18 found no relationship between the visual analogue scale score or 
the VISA-A score and the presence of neovascularisation.
In this study there was no relationship between neovascularisation at baseline and 
clinical outcome at one year. Zanetti et al.19 and de Vos et al.18 analysed the presence of 
neovessels at baseline related to outcome after 3 months of conservative treatment and 
reported similar results.
The use of a night splint in Achilles tendinopathy has been studied by Roos et al.9 They 
reported a pain reduction of 35–42% at one year follow-up in all patients treated with 
eccentric exercises, a night splint or a combination of both. There was no significant 
difference in pain reduction between these groups after one year.
At one-year follow-up another PDU device was used. Although the pulse repetition 
frequency did not differ much, comparison between baseline and one-year follow-up 
could be unreliable. Another weakness of this study is the high number of patients who 
were not able to attend for PDU examination at one year follow-up. An intention-to-treat 
analysis was used for the patients who received conservative treatment to avoid bias. 
However, because some patients received surgical treatment they were not comparable 
with the group of patients treated conservatively. Therefore, these tendons were scored 
as poor patient satisfaction with the presurgical VISA-A score. A type II error may have 
occurred in the present study; however, with a total of 62 patients analysed at follow-up 
a high power was achieved.
conclusion
Eccentric exercises, with or without a night splint, improved functional outcome after 
one year follow-up in patients with chronic Achilles tendinopathy. At follow-up there 
was no significant difference when a night splint was used in addition to an eccentric ex-
ercise programme. There was a continued improvement in functional outcome between 
3 months and one year. Thirty-seven per cent of the patients treated with eccentric 
exercises continued to perform them after the 3 months prescribed duration. The pres-
ence of neovascularisation at baseline did not predict pain and functional outcome at 
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one year follow-up. Seventy-one per cent of the tendons still showed some degree of 
neovascularisation at follow-up.
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AbstrAct
background: Eccentric exercises have the most evidence in conservative treatment 
of midportion Achilles tendinopathy. Although short-term studies show significant 
improvement, little is known of the long-term (>3 years) results.
Aim: To evaluate the 5-year outcome of patients with chronic midportion Achilles tendi-
nopathy treated with the classical Alfredson’s heel-drop exercise programme.
study design: Part of a 5-year follow-up of a previously conducted randomised con-
trolled trial.
Methods: 58 patients (70 tendons) were approached 5 years after the start of the heel-
drop exercise programme according to Alfredson. At baseline and at 5-year follow-up, 
the validated Victorian Institute of Sports Assessment–Achilles (VISA-A) questionnaire 
score, pain status, alternative treatments received and ultrasonographic neovascularisa-
tion score were recorded.
results: In 46 patients (58 tendons), the VISA-A score significantly increased from 49.2 
at baseline to 83.6 after 5 years (p<0.001) and from the 1-year to 5-year follow-up from 
75.0 to 83.4 (p<0.01). 39.7% of the patients were completely pain-free at follow-up and 
48.3% had received one or more alternative treatments. The sagittal tendon thickness 
decreased from 8.05 mm (SD 2.1) at baseline to 7.50 mm (SD 1.6) at the 5-year follow-up 
(p=0.051).
conclusion: At 5-year follow-up, a significant increase of VISA-A score can be expected. 
After the 3-month Alfredson’s heel-drop exercise programme, almost half of the patients 
had received other therapies. Although improvement of symptoms can be expected at 
long term, mild pain may remain.
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introduction
There are many conservative treatment options for chronic Achilles tendinopathy. Sys-
tematic reviews showed that the heavy load eccentric exercise programme has the most 
evidence of effectiveness in the treatment of chronic midportion Achilles tendinopathy.1-4 
The reviews demonstrated promising results on pain. However, there is limited evidence 
to show that eccentric exercises are more effective than other treatments in the man-
agement of tendinopathies. The exact mechanism involved in the eccentric exercises is 
unclear and there is an ongoing debate on the optimal load, frequency and duration.5,6 It 
is suggested that eccentric training might stimulate remodelling and tissue repair in ten-
dons, the so-called therapeutic mechano transduction.7 The classical heel-drop exercise 
programme first described by Alfredson et al.8 is time-consuming (180 repetitions per 
day for 12 weeks). The majority of the published studies have a maximum follow-up of 
1 year, and there is a lack of evidence about the long-term (>3 years) outcome.9-13 Three 
studies evaluated the long-term (>3 years) results of the eccentric exercises in chronic 
midportion Achilles tendinopathy.14-16 Only one study used the validated Victorian Insti-
tute of Sports Assessment-Achilles (VISA-A) questionnaire, but in that study the exercise 
regimen differed from that described by Alfredson et al.6 The VISA-A questionnaire is a 
validated score that measures pain and physical activity of the Achilles tendon.17 The test 
is developed to create an index of severity of Achilles tendinopathy.
So far, no long-term VISA-A score results (>3 years) are known of the widely used heel-
drop programme according to Alfredson. We evaluated the long-term clinical outcome of 
the heel-drop programme as described by Alfredson with the VISA-A score as the primary 
outcome measure. We also evaluated the ultrasonographic improvement 5 years after 
conservative therapy, alternative treatments received, pain status and patient satisfaction.
Methods
This study is the 5-year follow-up of an earlier published randomised controlled trial 
(RCT).13 The RCT evaluated the effect of the addition of a night splint to eccentric ex-
ercises in patients with chronic Achilles tendinopathy. At baseline, 58 patients (70 ten-
dons) with chronic midportion Achilles tendinopathy were included. Inclusion criteria 
at baseline were the presence of symptoms for more than 2 months and participation 
in sporting activities. All patients in the trial preformed the heel-drop programme as 
described by Alfredson et al.8 Half of the patients additionally received a night splint. The 
night splint had no significant influence on the VISA-A score at the 3-month and 1-year 
follow-up; all patients were therefore merged into one group for the 5-year follow-up.13,18 
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After completion of the heel-drop programme, patients were free to choose additional 
treatment(s); no instructions or recommendations were given to the patients.
The study protocol was approved by the Medical Ethics Committee of the Hospital 
(MEC05-21) and informed consent was given.
follow-up
All patients were approached by telephone for the 5-year follow-up. At the outpatient 
clinic, each patient completed the VISA-A score questionnaire and received an ultra-
sound examination by a single researcher. The VISA-A score was completed with minimal 
researcher assistance. Secondary outcome scores were obtained using a standardised 
questionnaire: (1) pain status (pain-free, not pain-free), (2) condition of the uninvolved 
tendon (affected, not affected), (3) subjective patient satisfaction towards the current 
status (categorised in poor, moderate, good, excellent), (4) received alternative treat-
ments after the heel-drop programme and, (5) continuation of the eccentric exercises 
(continued, stopped after the heel-drop programme).
ultrasound examination
For ultrasound examination, patients were asked to lie prone with their feet hanging over 
the edge of the table. During the examination, both Achilles tendons were evaluated in 
the sagittal plane for thickness and neovascularisation according to the Öhberg scoring 
system. This score was evaluated as 0 (no vessels visible), 1+ (one vessel mostly in the an-
terior part), 2+ (one or two vessels throughout the tendon), 3+ (three vessels throughout 
the tendon) and 4+ (more than three large vessels throughout the tendon). Two different 
power Doppler machines were used to examine the tendons: the MyLab25Gold (Esaote 
Piemedical, Maastricht, The Netherlands) and the BK Pro Focus (BK Medical, Herlev, 
Denmark). Both power Doppler machines used a frequency of 12 MHz, 0.5 PRF (pulse 
repetition frequency). The colour gain setting was optimised for low flow; putting the 
setting just below that level produces random noise, varying from 66% to 79%.19
statistical analysis
Differences in VISA-A score and tendon thickness between baseline and follow-up were 
evaluated using a sample t test. Differences between two categorical variables were 
evaluated using a χ2 test. Dependency analysis of the VISA-A score was performed using 
a non-repetitive analysis of covariance test. Statistical Package for the Social Sciences 
software (SPSS 17.0) was used. A P value of less than 0.05 was considered to be statistically 
significant.
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results
Attempts were made to contact all 58 patients (70 tendons). Six patients (six tendons) 
were not reachable for follow-up and five patients (five tendons) refused to participate 
(see figure 1). Three out of these five patients reported having no or minimal complaints 
of the Achilles tendon; unfortunately, further details are unknown. The VISA-A score and 
questionnaire results were obtained from 47 patients (59 tendons): 12 bilateral and 35 
unilateral. One patient (one tendon) was excluded from analysis due to a direct trauma 
to the Achilles tendon 2 days before the follow-up appointment, making the outcome 
non-representative. For general statistical analysis, 46 patients (58 tendons) were used. 
Five patients (six tendons) were not able to visit the hospital (no time or living abroad) 
but filled out the general questionnaire and the VISA-A score (see figure 1 for details). 
The ultrasonographic data consisted of information from 41 patients (52 tendons).
At follow-up, the mean age was 50.9 years, with a mean body mass index of 25.4 kg/m2 
(see table 1 for details). Baseline specifics are described by de Vos et al.13
Baseline  
70 tendons (58 patients)
Excluded (n=11)
6 patients were unreachable
4 patients refused to participate
1 patients did not attend several 
appointments
- VISA-A score 
- General questionnaire 
6 tendons (5 patients)
- VISA-A score 
- General questionnaire
- Ultrasound examination
53 tendons (42 patients)
Excluded (n=1)
1 had acute stump Achilles tendon 
trauma
Included for anaylis:
58 tendons (46 tendons)
figure 1: Flowchart of included patients.
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primary outcome: VisA-A score
The VISA-A score (n=58) improved significantly from 49.2 (SD 20.1) at baseline to 83.6 (SD 
14.9) at the 5-year follow-up (p<0.001). The VISA-A score (n=55) improved significantly 
between the 1-year follow-up and the 5-year follow-up from 75.0 (SD 25.0) to 83.4 (SD 
15.1) (p=0.006). See figure 2 for the trend line of the VISA-A score.
pain status
Of the patients, 39.7% reported being completely pain-free at the 5-year follow-up 
(mean VISA-A score 92.8, SD 8.8). The remaining 60.3% experienced some degree of pain, 
varying from only during extensive exercise to permanent pain (mean VISA-A score 77.5, 
SD 15.1). From the 34 patients with unilateral Achilles tendinopathy, 43.3% developed 
some degree of pain in the contralateral Achilles tendon.
figure 2: The VISA-A score in time.
table 1: Patient characteristics at 5-year follow-up
46 patients (58 tendons)
Mean age (years (range)) 50.9 (36–64)
Body mass index (kg/m2 (range)) 25.4 (19.9–33.5)
Unilateral/bilateral 34/12
No sports activity 4
Recreational sports 35
Competitive sports 7
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patient satisfaction
Patient subjective satisfaction towards the current status was excellent in 8.6% (mean 
VISA-A score 89.0, SD 8.0), good in 41.4% (mean VISA-A score 84.6, SD 16.3), moderate 
in 31.0% (mean VISA-A score 84.4, SD 15.2) and poor in 19.0% (mean VISA-A score 77.6, 
SD 13.5).
Alternative treatments
In total, 48.3% (22 patients) had received one or more alternative treatments, non-cus-
tom-made inlays (11 patients), surgery (6 patients), physiotherapy/massage/friction (6 
patients), shockwave therapy (2 patients), immobilisation cast (2 patients), Polidocanol 
injection (1 patient), platelet-rich plasma injection (1 patient), glyceryl trinitrate patches 
(1 patient), acupuncture (1 patient), non-steroidal anti-inflammatory drugs (1 patient) 
and rest for 2 years (1 patient). Of the group of patients treated with an alternative treat-
ment, 21.4% was completely pain-free. In the group of patients who did not receive an 
alternative treatment, 56.7% was completely pain-free. After completing the 3 months 
heel-drop programme in the original study, 67.2% (31 patients) never performed the 
eccentric exercises again. No correlation in pain status was found between patients who 
continued the eccentric exercises and those who did not (p=0.15).
ultrasonographic examination
The sagittal thickness decreased from 8.1 mm (SD 2.1) at baseline to 7.5 mm (SD 1.6) at 
the 5-year follow-up (n=50, p=0.051). At baseline, 58.8% had some degree of neovascu-
larisation (Öhberg score 1 to 4+). After 5 years, 47% showed neovascularisation during 
the ultrasonographic examination (n=51). There was no difference in increase in VISA-A 
score between the patients with neovessels at baseline (increase of 32.1 points, SD 22.1) 
and patients without neovessels at baseline (increase of 32.1 points, SD 23.7).
Fifty-four per cent of the patients without pain at follow-up had some degree of 
neovascularisation. No significant difference was found in tendon thickness at 5-year 
follow-up between the patients with and without symptoms (p=0.59).
factors influencing the VisA-A score
The VISA-A score at 5-year follow-up and the ΔVISA-A (= difference between baseline 
and the 5-year follow-up) score were not influenced by age (p=0.61 resp. p=0.18), sex 
(p=0.50 resp. p=0.39), body mass index (p=0.83 resp. p=0.50), duration of symptoms at 
baseline (p=0.11 resp. p=0.27), degree of neovascularisation at baseline (p=0.53 resp. 
p=0.81) and sagittal tendon thickness at baseline (p=0.43 resp. p=0.39).
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discussion
This is the first study evaluating the 5-years results of the Alfredson heel-drop pro-
gramme with the validated VISA-A score. The VISA-A score increased significantly from 
49.2 at baseline to 83.6 at the 5-year follow-up and from the 1-year follow-up to 5-year 
follow-up from 75.0 to 83.4 (p<0.01).
Until now the VISA-A score has only been used in one long-term follow-up study on ec-
centric exercises in Achilles tendinopathy.16 Silbernagel et al. reported a VISA-A score of 
90.5 at 5-year follow-up, 65% of symptom-free patients and approximately 6% receiving 
alternative treatments. In their study, the training programme lasted from 12 weeks to 6 
months and was performed under the supervision of a physiotherapist. Patients in the 
current study received very accurate instruction for the heel-drop programme and were 
instructed to do the exercises with pain. The compliance for the exercises was good/
excellent in the majority of the patients (>70%).13 The basic population of Silbernagel 
et al. showed many similarities with our population, however, no competitive athletes 
were included in the study of Silbernagel et al. Maffulli et al.20 suggested there could be 
a difference in response to eccentric training in the Scandinavian population. Several 
Scandinavian studies have demonstrated good/excellent short-term results from the 
eccentric exercises in the treatment of chronic Achilles tendinopathy.9-12 In recent years, 
differing results have been found by non-Scandinavian studies showing only moderate 
short-term results.13,21,22 The long-term Scandinavian studies evaluating eccentric exer-
cises in chronic Achilles tendinopathy suggest a good long-term prognosis.14–16 Further 
studies will be needed to reveal if there is a genetic explanation for this difference.23
Two other studies have reported long-term effects of the heel-drop programme used 
in this study in patients with Achilles tendinopathy.14,15 However, neither of them used 
the validated VISA-A score. Ohberg et al. showed that 22 of 25 (88%) patients were 
satisfied with the treatment at a mean follow-up of 3.8 years (range 1.6–7.75). The sec-
ond long-term follow-up study reported that 65% of the patients had no or mild pain 
after 4.2 years (range 29–58 months).14 In our study, 39.7% of the study population was 
completely pain-free at the 5-year follow-up. Almost half of our patients had received 
one or more alternative treatments. These secondary subjective outcomes suggest a 
discrepancy with the significant increase of the primary outcome score. For advise to 
patients it implies that a quantified improvement can be expected, but mild remaining 
pain symptoms may be present at long term.
Ultrasonographic evaluation demonstrated a comparable decrease in tendon thick-
ness from 8.8 mm before the heel-drop programme to 7.6 mm at follow-up. However, 
the clinical relevance of this minor decrease is questionable. In recent years, a debate has 
arisen about the meaning and the significance of neovascularisation in Achilles tendons. 
Some studies have found a correlation between the patient’s symptoms and the degree 
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of neovascularisation,24-26 and others found that the presence of neovascularisation did 
not per se indicate a disease state.27-31 Also the circumstances during the examination, 
for example, activity just before the measurement, was not controlled and is unknown. 
This study found that the VISA-A score was not related to the degree of neovascularisa-
tion. Further research is needed to understand the relevance of neovascularisation in 
Achilles tendons.
This study has some limitations. The 11 dropouts might have influenced the outcome. 
In a best case scenario analysis where the dropouts have the best outcome score, 50% 
of the patients would be pain-free. However, the value of this non-validated subjective 
outcome measurement is questionable. Patients had to answer questions concerning 
the last 5 years, which may have given recall bias. The long-term outcome could be 
influenced by the alternative treatments that the patients received after completion 
of the heel-drop programme. However, of the patients who did not receive alternative 
treatments, 56.7% were completely pain-free after 5 years. Robinson et al.17 recom-
mended to use the VISA-A score in a homogenous group of athletes. Especially at 
long-term follow-up, the VISA-A score questionnaire can be subject to other influences 
than solely the symptoms of the Achilles tendinopathy. Factors like general ageing 
and new comorbidity may have influenced the outcome in this study. Finally, the ul-
trasonographic examinations at baseline and at follow-up were performed by different 
observers. However, in an earlier study, an excellent interobserver reliability of grading 
the neovascularisation was found.32
conclusion
This is the first study evaluating the 5-year results of the widely used heel-drop exercise 
programme as described by Alfredson et al. with the validated VISA-A score. At 5-year 
follow-up, the VISA-A score increased significantly. After the 3-month eccentric training 
programme, almost half of the patients had received other therapies. Although improve-
ment of symptoms can be expected at long term, mild pain may remain.
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AbstrAct
background: Achilles tendinopathy is a common disease among both athletes and 
in the general population in which the use of platelet-rich plasma has recently been 
increasing. Good evidence for the use of this autologous product in tendinopathy is 
limited, and data on longer-term results are lacking.
purpose: To study the effects of a platelet-rich plasma injection in patients with chronic 
midportion Achilles tendinopathy at 1-year follow-up.
study design: Randomized controlled trial; Level of evidence, 1.
Methods: Fifty-four patients, aged 18 to 70 years, with chronic tendinopathy 2 to 7 cm 
proximal to the Achilles tendon insertion were randomized to receive either a blinded 
injection containing platelet-rich plasma or saline (placebo group) in addition to an 
eccentric training program. The main outcome was the validated Victorian Institute of 
Sports Assessment–Achilles score. Patient satisfaction was recorded and ultrasound 
examination performed at baseline and follow-up.
results: The mean Victorian Institute of Sports Assessment–Achilles score improved 
in both the platelet-rich plasma group and the placebo group after 1 year. There was 
no significant difference in increase between both groups (adjusted between-group 
difference, 5.5; 95% confidence interval, –4.9 to 15.8, P = .292). In both groups, 59% of 
the patients were satisfied with the received treatment. Ultrasonographic tendon struc-
ture improved significantly in both groups but was not significantly different between 
groups (adjusted between-group difference, 1.2%; 95% confidence interval, –4.1 to 6.6, 
P = .647).
conclusion: This randomized controlled trial showed no clinical and ultrasonographic 
superiority of platelet-rich plasma injection over a placebo injection in chronic Achilles 
tendinopathy at 1 year combined with an eccentric training program.
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introduction
Chronic tendinopathy is frequent in both athletes and the general population.25 The 
poor regenerative capability of tendons seems to play a major role in this chronic 
disease. Tendinosis, which is characterized by degeneration and disorganization of col-
lagen fibers, increased vascularization, and irregular cellularity, is commonly found on 
histological examination in tendinopathy. Classic inflammation is minimal or absent in 
this condition.1,6,14,22,28 Because of this finding, the initially used term tendinitis has been 
replaced by tendinopathy. The Achilles tendon is one of the most vulnerable tendons.26,37 
The diagnosis of Achilles tendinopathy can be made in the presence of a painful swollen 
tendon with impaired function.26
Regenerative medicine is being studied more intensively in the field of tendinopathy. 
It is assumed that growth factors and/or (stem) cells are able to reverse the degenera-
tive process.4 Platelet-rich plasma (PRP) is a popular application form for growth factor 
release. With the increase of platelet concentration in this product, the amounts of 
several growth factors are also increased.18 Growth factors act on different aspects of 
tendon repair, including angiogenesis, chemotaxis, and cell proliferation by activating 
intracellular signal-transduction pathways.5,13
Sports orthopaedic physicians have increasingly been using PRP as treatment for 
tendinopathy. A recent systematic review showed that high-quality randomized clini-
cal trials and midterm and long-term follow-up results are lacking.15 Of the few studies 
reporting high success rates for PRP treatment in tendinopathy,19,24,27,32 only 1 trial had 
an adequate control group with 1-year follow-up.32 None of these publications included 
a standardized ultrasonographic evaluation of tendon structure. The short-term results 
of the current study were reported earlier. No additional effects of PRP injection to 
eccentric exercises were found after 6 months.17 However, biologic agents could bring 
forth a response that becomes pronounced over time. In a recent randomized controlled 
trial on the effects of PRP in lateral epicondylitis, there was no difference in outcome 
between PRP injections and corticosteroid injections at 3 months, whereas at 1 year the 
PRP group did significantly better.32
Ultrasonography can be used for the evaluation of therapy in tendinopathy.7 Recently, 
ultrasonographic tissue characterization (UTC) was introduced as a reliable method for 
quantification of tendon structure.41 The method calculates the 3-dimensional stabil-
ity of the echo pattern over continuous cross-sectional images of the tendon and was 
extensively evaluated in equine studies using histology as the reference. This new tech-
nique, with a high interobserver and intraobserver reliability, can discriminate between 
symptomatic and asymptomatic human tendons.43
94 Chapter 7
Neovascularization score alters during treatment of Achilles tendinopathy. Although 
the interpretation of neovascularization remains unclear, different trials used neovascu-
larization as an objective parameter in their results.12,30,47
In further follow-up of the 6-month clinical results,17 the aim of the current study is 
to evaluate both the clinical and the ultrasonographic tissue effects of a PRP injection 
versus placebo in patients with chronic Achilles tendinopathy after 1 year.
MAteriAls And Methods
This is a 1-year follow-up study of a randomized controlled trial.17 Materials and methods 
were as extensively described in the article by de Vos et al.17 and reported in the study 
protocol registered at clinicaltrials.gov (Identifier: NCT00761423).
patients
Patients were recruited in a large district hospital at the department of sports medicine. 
Inclusion criteria were patients with the clinical diagnosis of Achilles tendinopathy with 
a minimal duration of symptoms of 2 months. Patients were excluded if they already 
had performed a full eccentric exercise program or already received a PRP injection in 
the Achilles tendon. Other exclusion criteria were known presence of a systemic illness, 
presence of other musculoskeletal injury (such as insertional disorder or tendon rup-
ture), use of fluoroquinolones, and presence of pregnancy.
procedures
Both the PRP injection (4 mL) and a saline injection (4 mL) were prepared for each pa-
tient. For the PRP injection, 54 mL of whole blood was collected from the cubital vein; 6 
mL of citrate was added to prevent clotting. The collected blood was centrifuged for 15 
minutes using the Recover Platelet Separation Kit (type Gravitational Platelet Separation 
III), and 0.3 mL of 8.4% sodium bicarbonate buffer was added.18 No calcium chloride or 
thrombin was added to activate the platelets before injecting because we assumed that 
platelets are also activated by collagen.20
randomization
A block randomization was performed with a block size of 12 participants. The patients 
were randomized into 1 of the treatment groups by choosing a blank sealed envelope. 
The content of this envelope was only visible for 1 unblinded independent sports 
medicine physician (A.W.) who selected the randomized injection and blinded it with a 
covering sleeve.
PRP for Achilles tendinopathy: one year follow-up 95
ch
ap
te
r 7
intervention
First, the skin and subcutaneous tissue were anesthetized with 2 mL of 0.5% Marcaine. 
The injection was performed under ultrasonographic guidance by an experienced 
sports physician who was also blinded to the allocated treatment. At 3 different needle 
locations, 5 little aliquots were injected (with a total amount of 4 mL). After the injection, 
patients had to avoid sports activities for 4 weeks; in the second week, they performed 
a stretching program. After this, all patients started an eccentric exercise program for 12 
weeks.3
follow-up
Recruitment, inclusion, and follow-up contacts at 6, 12, and 24 weeks after injection were 
performed by one researcher (R.J.d.V.). One-year follow-up was performed by another 
researcher (S.d.J.) who was also blinded for the allocated intervention. Both clinical and 
ultrasonographic outcomes were assessed at all time points. Patients remained blinded 
until 1-year follow-up.
clinical outcome Measures
The primary outcome was the Victorian Institute of Sports Assessment–Achilles (VISA-A) 
score (validated questionnaire for outcome in Achilles tendinopathy). Other outcome 
measures were subjective patient satisfaction (scored as moderate, poor, good, or excel-
lent) and return to sports activity (scored as not active in sports, no return to sports, 
returning to sport but not in desired sport, returning to desired sport but not at the 
preinjury level, or returning to preinjury level in the desired sport). For analysis of patient 
satisfaction, patients reporting good or excellent satisfaction were reported as satisfied. 
For return to sports activity, cutoff was made for return to desired sport on preinjury 
level.
sonographic evaluation
Tendon structure was evaluated quantitatively by means of UTC (UTCimaging, Stein, 
the Netherlands). With the ankle joint in 15° of dorsal flexion, a 10-MHz linear-array 
transducer (Smartprobe 10L5, Terason 2000, TeraTech, Rockville, Maryland) was moved 
automatically along and perpendicular to the Achilles tendon’s long axis over a distance 
of 9.6 cm. The transverse images collected at regular distances of 0.2 mm were used 
to reconstruct a 3-dimensional data block. The stability of the echo pattern over con-
tiguous images was analyzed by means of custom-designed algorithms (UTCimaging) 
and results in discrimination of 4 echo types: Echo types I and II represent more or less 
organized (secondary) tendon bundles; echo types III and IV represent smaller, disor-
ganized, and more amorphous or fibrillar structures.42 In transverse and sagittal planes 
of view, the maximum anterior-posterior diameter was determined and measured. At 5 
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points around this thickest part, from 1.5 cm proximal to 1.5 cm distal to the maximum 
anterior-posterior diameter, the border of the tendon was marked and intermediate 
borders interpolated, creating a volume with an overall length of 3 cm. Proportions of 
the 4 echo types were measured within this volume. The sum of echo types I and II, 
representing more or less organized secondary tendon bundles, was used for statistical 
analysis. Ultrasound examination at the 1-year follow-up was performed by another 
researcher (S.d.J.). The interobserver reliability between the 2 examiners (R.J.d.V. and 
S.d.J.) was tested in 17 tendons at 2 different time points within 1 week. The reliability 
appeared to be excellent, with an intraclass correlation coefficient of 0.89 and a mean 
difference of 0.9%.
neovascularization
Neovascularization was scored using the modified Öhberg scoring system.23,38 In this 
scoring system, scores were determined as 0 (no vessels), 1+ (1 vessel, mostly anterior 
to the tendon), 2+ (1 or 2 vessels throughout the tendon), 3+ (3 vessels throughout the 
tendon), or 4+ (more than 3 vessels throughout the tendon). The degree of neovascular-
ization can be measured with an excellent interobserver reliability (intraclass correlation, 
0.85).38 This color Doppler ultrasonography examination was performed with a linear 
high-frequency 12- to 15-MHz transducer (MyLab30, Esaote Piemedical, Maastricht, 
the Netherlands) with Doppler gain at 79% and Doppler frequency at 6.6 MHz. Patients 
were laying prone on the examination table with their feet hanging over the edge. The 
neovascularization of the tendon was scored in longitudinal and transverse planes.12,16
statistics
The sample size calculation showed that with a power of 80% (2-sided testing at a 
significance level of .05) and compensating for 10% loss to follow-up, a sample size of 
27 participants in each group was needed to show a difference of 12 points on the VISA 
score (SD, 15). Statistical analyses were performed using social sciences software (SPSS 
16.0, SPSS Inc, an IBM Company, Chicago, Illinois). Between-group differences at long-
term follow-up in the VISA-A score and ultrasonographic outcome measurements were 
estimated using a repeated-measurement general linear model including all measure-
ment time points. Adjustments were made for variables that influenced the outcome 
measurement with P  <  .10. For between-group differences in nominal outcomes, a 
generalized estimating equations model was used. Positive values in between-group 
differences favor the PRP group. A difference of P < .05 was considered to be statistically 
significant. Patients were analyzed on an intention-to-treat basis.
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results
patients
At baseline, 54 of the 99 eligible patients were willing to participate, met the inclusion 
criteria, and were randomized into the 2 treatment groups. The mean age was 49.7 years 
(range, 26-70 years), mean body mass index (weight in kg/height [m]2) was 26.5 (range, 
20.2-35.3), and the mean duration of symptoms was 62.6 weeks (median, 32 weeks; 
range, 8-520 weeks). There were no significant differences in baseline characteristics 
between the 2 groups.
No patients were lost to follow-up (Figure  1). One patient was not able to visit the 
center for ultrasonographic examination but did complete the clinical outcome mea-
sures by mail. After 24 weeks, 4 patients in the PRP group decided to undergo another 
treatment because of failure to improve. These treatments included orthotics (n  =  1), 
extracorporeal shockwave therapy (n = 3), and glyceryl trinitrate patches (n = 1). In the 
placebo group, 1 patient received glyceryl trinitrate patches. No complications were 
reported between 24-week and 1-year follow-up.
 
Assessed for eligibility (n=99) 
Excluded (n=45) 
   Not meeting inclusion criteria (n=8) 
   Declined to participate (n=30) 
   Meeting exclusion criteria (n=7) 
Excluded from clinical analysis (n=0) 
Excluded from UTC-analysis (n=1) 
 Failed to attend the visit 
Excluded from CDU-analysis (n=1) 
 Failed to attend the visit 
Lost to follow-up (n=0) 
Allocated to PRP group (n=27) 
Lost to follow-up (n=0) 
Allocated to placebo group (n=27) 
Excluded from clinical analysis (n=0) 
Excluded from UTC-analysis (n=3) 
 Skin problem (n=1) 
 Bad scanning technique (n=2) 
Excluded from CDU-analysis (n=0) 
Allocation 
Analysis  
1 year 
Follow-Up  
1 year 
Randomized (n=54) 
Enrollment 
figure 1: Flowchart of patients in the study. CDU, color Doppler ultrasonography; PRP, platelet-rich plasma; 
UTC, ultrasonographic tissue characterization.
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clinical outcome
At 1-year follow-up, the VISA-A score improved significantly by 31.6 points (95% confi-
dence interval [CI], 22.2-40.9) from 46.7 (95% CI, 40.3-53.1) at baseline to 78.2 (95% CI, 
68.0-88.5) in the PRP group and by 25.0 (95% CI, 18.0-32.0) points from 52.6 (95% CI, 
54.1-60.2) to 77.6 (95% CI, 70.8-84.4) in the placebo group. In the general linear model, 
adjustments were made for baseline VISA-A score (P = .023) and duration of symptoms 
(P =  .023). The adjusted between-group difference at 1-year follow-up was not signifi-
cant (5.5 points on VISA-A score; 95% CI, −4.9 to 15.8). The VISA-A scores at all follow-up 
moments for both groups are shown in Figure 2.
After 1 year in both groups, 16 patients (59.3%) were satisfied with their allocated 
treatment. Adjusted between-group difference for subjective patient satisfaction after 1 
year was −2.7% (95% CI, −23.5 to 18.1; P = .801).
In the PRP group, 56.5% of the patients returned to their previous sports levels in 
the desired sport, compared with 41.7% in the placebo group. The adjusted between-
group difference for return to sports at 1-year follow-up was 1.8% (95% CI, −24.5 to 28.1; 
P = .894).
sonographic outcome
The percentages of the more or less organized echo types I and II increased 7.2% (95% 
CI, 3.4-11.0) in the PRP group from 76.9% (95% CI, 72.6-81.1) at baseline to 83.7% (95% 
CI, 79.6-87.9) at 1-year follow-up. In the placebo group, these echo types increased 
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figure 2: Changes in mean Victorian Institute of Sports Assessment–Achilles (VISA-A) score for both 
groups. There was improvement in VISA-A score within both groups but no significant difference between 
the groups.
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8.4% (95% CI, 3.1-13.6) from 72.1% (95% CI, 67.7-76.5) to 81.3% (95% CI, 77.3-85.3). In 
the general linear model, adjustments were made for baseline value echo type I and II 
(P < .001). Between-group difference at 1-year follow-up was 1.2% (95% CI, −4.1 to 6.6; 
P = .647). Alterations in all echo types in the PRP group (Figure 3A) and control group 
(Figure 3B) are plotted in Figure 3.
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figure 3: A, changes in UTC echo types in PRP group. Echo type I increased over time, whereas echo type 
II remained stable. Echo types III and IV decreased slightly. B, changes in UTC echo types in placebo group. 
Echo type I increased over time, whereas echo type II remained stable. Echo types III and IV decreased 
slightly.
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Maximum anterior-posterior diameter of the Achilles tendon decreased in the PRP 
group from 9.8 mm (95% CI, 9.1-10.5) at baseline to 9.0 mm (95% CI, 8.2-9.8) at 1-year 
follow-up. This was not significantly different from the decrease in the placebo group 
from 9.8 mm (95% CI, 8.6-11.1) at baseline to 8.6 mm (95% CI, 7.6-9.5) after 1 year. 
Between-group difference was 0.4 mm (95% CI, −0.8 to 1.7; P = .457).
Mean neovascularization score increased in the PRP group in the first 12 weeks from 
2.3 (95% CI, 1.8-2.7) to 3.0 (95% CI, 2.6-3.5) and in the placebo group from 2.2 (95% 
CI, 1.6-2.7) to 2.5 (95% CI, 2.1-2.9). From 12 weeks to 1-year follow-up, a decrease was 
found in both groups, to 1.4 (95% CI, 0.8-2.0) in the PRP group and 1.2 (95% CI, 0.7-1.7) 
in the placebo group. Between-group difference at 1-year follow-up was 0.1 point (95% 
CI, −0.6 to 0.9; P = .714). Mean neovascularization scores for both groups are shown in 
Figure 4.
discussion
In this double-blind randomized placebo-controlled clinical trial with 1-year follow-up, 
no clinical or sonographic benefit of a PRP injection was found. These results are in line 
with the findings after 6 months.17 This is the first trial using standardized sonography in 
1-year clinical results of PRP therapy in Achilles tendinopathy.
In different types of tendinopathy, promising results for PRP therapy have been 
published recently.19,24,27,31 Two pilot studies reported high patient satisfaction and pain 
reduction after PRP therapy24,27; the group sizes of these studies, however, were small, 
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figure 4: The alterations of the mean neovascularization score within both groups. In both groups, the 
neovascularization score continued decreasing after the increase at the 12-week follow-up.
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and a control group was lacking. Filardo et al.19 selected a control group with patients 
with moderate patellar tendinopathy receiving a regular physical therapy program 
versus patients with nonresponding patellar tendinopathy receiving multiple PRP 
injections. They found equal clinical improvements after 6 months in both groups. In a 
recent publication, Gaweda et al.21 studied the effect of PRP in 14 patients with Achilles 
tendinopathy without the use of a control group and found significant improvement in 
VISA-A score after 18 months.
The only other randomized controlled trial on PRP therapy in tendinopathy showed 
a significant benefit of PRP injection in wrist extensor tendinopathy compared with 
corticosteroid injection after 1 year.32 Comparing the pattern of visual analog scale 
score with the VISA-A score in our study, the deviating course in the control group of 
Peerbooms et al.32 is remarkable. Unlike our study, the control group received a corti-
costeroid injection instead of a placebo injection, which very well may have negatively 
affected the outcome in the control group.40 In addition, there may be differences in the 
natural healing response between load-bearing tendons, such as the Achilles tendon, 
and non–load-bearing tendons, such as the wrist extensors. Although a tennis elbow is 
a self-limiting injury,34 Achilles tendinopathy seems not to be.35
It is possible that the needling during the injection could influence the outcome in 
both groups. Brown et al.8 compared aprotinin injections and eccentric exercises with 
a saline injection and eccentric exercises. They found similar improvement in both the 
aprotinin and placebo groups. A healing response can be initiated by needle trauma 
or local bleeding.33 Another hypothesis for the positive effects in both groups is the 
increase in peritendinous volume, thereby destroying the vascular and neural growth 
that is thought to be the source of pain.10 The increase of neovessels after the injection 
contradicts this theory. It is not certain that the injected volume stays intratendinous for 
a sustained period or leaks, for example, to the peritendinous space. Using an injection 
procedure similar to the procedure in this study, Wiegerinck et al.46 showed an equal dis-
tribution of intratendinously injected volumes in the Achilles tendons of human cadav-
ers. The assumption that PRP only has great potency in traumatic lesions is invalidated 
by Schepull et al.36 They found no benefit of PRP in treatment of Achilles tendon rupture. 
Cell therapy has recently been proposed as the most promising therapy for degenerated 
tendons,48 but further research in this field is required.
The sample size of this study was calculated to detect a minimal clinically relevant 
difference of 12 points on VISA-A score. After 1 year, this difference lies within the 95% CI 
of the adjusted between-group difference (−4.9 to 15.8). Although we cannot exclude a 
clinically relevant effect of PRP, which was the case at 6 months of follow-up, the chance 
of such an effect at long term with this CI seems unlikely.
Furthermore, no beneficial effect of PRP on ultrasonographic tendon structure and 
neovascularization was found in our study. Both the PRP group and placebo group im-
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proved tendon structure, but no significant differences between the groups were found. 
These results are in line with the ultrasonographic changes after 6 months.16 In equine 
studies, a correlation between UTC and histologic findings was reported.41,42 In humans, 
UTC can differentiate between symptomatic and asymptomatic tendons43; however, a 
clear correlation between tendon structure measured with UTC and clinical outcome 
after 6 months cannot be found (de Vos et al., unpublished data). In both groups, neo-
vascularization continued decreasing after the increase at the 12-week follow-up. The 
same pattern was described by Alfredson and Öhberg,2 reporting neovascularization 
after sclerosing injections for Achilles tendinopathy. In a previous study on splinting 
in addition to eccentric exercises, such a pattern was not shown,12 suggesting that the 
fluctuations in vascularization may be a direct response to needle trauma.
A limitation of this study is that the exact composition of the PRP is unknown. The 
platelet separation system used in this trial has been examined in other studies that re-
ported sufficient platelet counts.27 However, there are a variety of methods for preparing 
PRP and various forms in which it can be administered. The value of altering variables 
like platelet count, injected volume, number of injections, preactivation, and presence 
of leukocytes could not be determined in this study due to the design. More research 
will be needed to assess the effects of altering these variables on the clinical outcome. 
At this point in time, there are 7 level 1B studies on PRP in acute and chronic tendon or 
ligament injuries.9,17,29,32,36,39,44 In all these studies, very differing preparation and admin-
istration techniques were used. None of these high-quality studies showed a statistically 
significant superior effect compared with placebo.
Some researchers believe PRP should only be reserved for use in severe cases.11 In 
the field of tendinopathy research, there is, however, no validated classification for the 
severity of complaints. Our study population had a mean duration of symptoms of 16 
months (range, 2-130 months). In our analysis, the duration of symptoms and baseline 
VISA-A score were found to be important predictors for VISA-A improvement. For this 
reason, adjustments were made for these values in the analysis. It is questionable 
whether PRP treatment can only play a role in patients with resistant tendinopathy that 
fails to respond to eccentric loading or that the eccentric exercise program dominates 
the effect of PRP. An animal study revealed that PRP needs to be combined with me-
chanical stimulation to achieve tendon healing.45 Furthermore, all published studies on 
PRP treatment in tendinopathy combined it with strengthening programs.15
Based on the current results, no benefit of an injection with PRP, in addition to ec-
centric exercises in patients with chronic midportion Achilles tendinopathy, was shown 
at 1-year follow-up.
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conclusion
A PRP injection in addition to eccentric exercises did not result in clinical improvement 
and/or improved structural reorganization on ultrasound after 1 year in chronic midpor-
tion Achilles tendinopathy, compared with a placebo injection.
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epideMiology
The optimal management of a health disorder starts with an accurate description of the 
problem. We are the first reporting a prevalence of 2.01 per 1000 person years for Achil-
les tendinopathy in the general population (chapter 2). This prevalence was reproduced 
by Albers and colleagues, who found a prevalence rate of 2.35 per 1000 person years.1 
The 35% sports-related origin in our prevalence study might be an underestimation. 
From literature we know that approximately 30% of Achilles tendinopathy patients are 
sedentary.2 This confirms the idea that overload is not the only pathomechanism of ten-
dinopathy. Moreover, previous animal studies showed that unloading has an important 
detrimental effect on mechanical properties tendons.3,4
Aetiology
Scott and colleagues debate the role of adiposity and hyperlipidemia in tendinopathy.5 
They suggest that both systemic hyperlipidemia as higher mechanical load contribute 
to the development of tendon pathology (tendinopathy, ruptures or ultrasound ab-
normalities. We only measured baseline BMI in our clinical studies and did not find an 
association between BMI and primary outcome of the study (VISA-A score). We did not 
measure BMI at the follow-up moments, to evaluate the influence of weight loss on the 
outcome. In chapter 5 we found a strong association of BMI with poorer ultrasonographic 
tendon structure in both diabetes type 1 and diabetes type 2 patients. After correction 
for BMI, diabetes type 2 patients had still poorer tendon structure than controls. This is 
in accordance with the review of Abate et al. who describe the combination of diabetes 
and obesity as a potential cause of tendon damage.6
conserVAtiVe treAtMent
In our clinical trials (chapter 6.1, 6.2 and 7) we combined the interventions with an 
eccentric exercise programme of Alfredson.7 There is strong evidence for the prescrip-
tion of an eccentric exercise programmes of 12 weeks in cases with chronic Achilles 
tendinopathy and this evidence has not changed over the last ten year.8-10 In a five year 
follow-up of patients treated with eccentric exercises, we found disappointing patient 
satisfaction, despite of a continuing increase in VISA-A score (chapter 6.2). The VISA-A is 
a robust tool that can be used extensively for initial assessment of and following treat-
ment for Achilles tendinopathy. However, as 40% of the questions are about activity, 
there is a great variety in outcome between athletes and sedentary patients.11 For the 
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related questionnaire in patellar tendinopathy (VISA-P) a minimum clinically important 
difference of 13 points was defined.12 In our studies (described in chapter 6.1 and 7) 
we found an improvement of more than 13 points after three months. While there is 
no clear minimum score for return to sports, success rates of a therapy can not only be 
based on VISA-A score.
inJection treAtMent
The study on injection treatment with platelet-rich plasma (chapter 7) in this thesis lacks 
to show effect over placebo injections. One can question whether the investigated injec-
tions arrived at the exact site of injury. The injection was ultrasound guided.  A cadaveric 
study (chapter 3) described good distribution of intratendinous injected substance into 
the Achilles tendon as well as peritendinously independent from post injection ankle 
movements.
ultrAsonogrAphy
Ultrasonographic tissue characterisation was used to monitor tendon structure in chap-
ter 5 and 7. In chapter 4 we lack to show a relationship between the amount of pain 
and degree of neovascularization. Many imaging studies indicate that abnormalities can 
exist in asymptomatic tendons.13-15 Clearly, there is a missing link between the amount 
of pain and the degree of tendon structural disorganisation on ultrasound.
This is similar to radiologic imaging in patients with knee osteoarthritis, where a 
discordance is present between pain levels and radiographic signs of osteoarthritis.16 
Another typical similarity between tendinopathy and osteoarthritis is morning stiffness, 
however one large difference is the fact that pain osteoarthritis continues with ageing, 
while painful tendons seem to disappear in the very elderly.
continuuM of tendon pAthology
A comparison between tendinopathy and osteoarthritis was also made by Cook and 
Purdam.17 They introduced a model about the ‘continuum of tendon pathology’ based 
on a continuum from a reversible stage through to advanced osteoarthritis.18 In their 
model they describe three distinct stages: (1) reactive tendinopathy,(2) tendon disrepair 
(failed healing) and (3) degenerative tendinopathy. This interesting model is mainly 
based on disbalance in loading and the cause of pain cannot explained by it.
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pAin in tendinopAthy
Rio and colleagues described the role of pain in tendinopathy.19 Physiologic (or nocicep-
tive) pain is a helpful warning sign in case of impending tissue damage or inflammation. 
Pain in chronic tendinopathy seems to be based on this nociceptive pathway, but also 
central pain mechanisms might play a role. Van Wilgen et al. found some evidence for 
central sensitization in patellar tendinopathy.20,21 Because classical inflammation and in-
nervation pattern seem not contributing to the pain in tendinopathy, Rio et al. suggest 
that changes in matrix and cell function are potential sources of nociception in tendons.
We did not measure whether our therapies, altered the matrix and cell function in the 
patients, but there was no benefit on clinical outcome compared Possibly a combined 
therapy on pain sensitization would result in a better outcome.
future prospects
Future research should focus on the etiology and the role of pain in chronic tendinopa-
thy. For example the role of adiposity in tendinopathy should be further investigated. 
Therefore, clinical trials should include BMI, fat percentage and blood lipid measure-
ment at start of the study and during follow-up moments.
However, patients who lack to respond to the eccentric exercise can possibly not wait 
for this holy grail and need an evidence based treatment. Therefore, high quality ran-
domized clinical trials on new treatment options for patients with Achilles tendinopathy 
who do not respond to an eccentric exercise programme should be conducted in the 
future. In order to evaluate the effect of treatments in tendinopathy a minimum clini-
cally important change (MCIC) for the VISA-A questionnaire must be determined.
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Chronic Achilles tendon pathology is a big problem in sports involving running and 
jumping. However, it is not always related to excessive physical activity. Recalcitrant 
Achilles tendons may cause pain for years and are often resistant to any form of treat-
ment. In the end, chronic Achilles tendon complaints may be self-limiting. The aim 
of this thesis was to elucidate the effect of different treatment options in midportion 
Achilles tendinopathy, with optimizing current diagnostic methods. For this purpose we 
conducted two randomised controlled trials, a case control study, a cadaveric study, and 
a cross sectional study.
The aim of the cross sectional study in chapter 2 was to ascertain the frequency of mid-
portion Achilles tendinopathy seen in the general practitioner (GP) setting. We were the 
first to report an incidence rate of Achilles tendinopathy of 1.85 per 1000 registered 
patients, and of 2.35 in the adult population.
In chapter 3 we evaluated the effect of two post injection protocols after intratendi-
nous platelet-rich plasma injection on the spread in and around the Achilles tendon. 
We measured the spread after simulated ankle motion and after a 15 minutes rest post 
injection in a cadaveric model. We found all ten Achilles tendons to have been gradu-
ally infiltrated with platelet-rich plasma after mid-portion injection. No difference was 
found in intratendinously and peritendinously spread between the two post-injection 
protocol.
The prospective cohort study in chapter 4 used a large database of three clinical trials, 
with over 500 paired measurements, there is no relationship between the amount of 
pain and degree of ultrasonographically measured neovascularization in symptomatic 
tendons. Neovascularisation was not present in 24% of chronic symptomatic Achilles 
tendons. A longer duration of symptoms was not related to presence of neovasculariza-
tion. A decrease in neovascularization over time during the study was not related with a 
better improvement in the VISA-A score.
The primary aim of the case-control study in chapter 5 was to compare Achilles tendon 
structure in type 1 diabetes and type 2 diabetes patients with healthy age-matched 
controls. Secondary aim was to correlate skin autofluorescence (AF) as a general indica-
tor of advanced glycation end products (AGEs) with Achilles tendon structure. Further-
more, we investigated prognostic baseline characteristics for Achilles tendon structure. 
This study showed that people with type 2, and potentially also type 1 diabetes, have 
compromised structure of the mid-portion of the Achilles tendon. Although patients 
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with diabetes mellitus have elevated skin AF scores compared with their controls, the 
difference in ultrasonographic tendon disintegration seems to be based mainly on body 
mass index (BMI).
chapter 6.1 and 6.2 contain the one year and five year follow-up of a prospective 
randomised trial on the effects of a heavy load eccentric exercise programme compared 
with a heavy load eccentric programme in combination with the use of a night splint 
in patients with chronic Achilles tendinopathy. Eccentric exercises, with or without a 
night splint, improved functional outcome after one year follow-up. At follow-up there 
was no significant benefit of using a night splint in addition to the eccentric exercise 
programme. There was a continued improvement in functional outcome (VISA-A score) 
between one year and five year follow-up. Between finishing the 3-month eccentric 
training programme and the five year follow-up, almost half of the patients had received 
other therapies. Only 40% of the patients reported being completely pain-free at the 
5-year follow-up.
The aim of the follow-up study of a double blinded randomised controlled trial, de-
scribed in chapter 7, was to evaluate both the clinical and the ultrasonographic tissue 
effects of a PRP injection versus placebo in patients with chronic Achilles tendinopathy 
after 1 year. A PRP injection in addition to eccentric exercises did not result in clinical 
improvement or improved structural reorganization on ultrasound, compared with a 
placebo injection.
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Chronische achillespees aandoeningen vormen een groot probleem voor sporters 
met hardloop- en sprong belastingen. Het is echter niet altijd gerelateerd aan fysieke 
overbelasting. De pijn bij recalcitrante Achillespees tendinopathie kan jaren aanhouden 
zonder te reageren op behandeling. Uiteindelijk lijkt de aandoening wel self-limiting te 
zijn. Het doel van dit proefschrift was om verschillende behandelopties van midportion 
Achilles tendinopathie te onderzoeken met betrouwbare diagnostische methoden. 
Hiervoor voerden we twee gerandomiseerde klinische studies, een case-control studie, 
een kadaver studie en een cross-sectionele studie uit.
Het doel van de cross-sectionele studie in hoofdstuk 2 was het vaststellen van het 
voorkomen van mid-portion Achilles tendinopathie in de huisartsenpraktijk. Dit was de 
eerste studie die voor achilles tendinopathie een incidentie van 1.85 per 1000 geregis-
treerde patiënten laat zien en een incidentie van 2.35/1000 in de volwassen populatie.
In hoofdstuk 3 onderzochten we het effect van twee post-injectie protocollen op de 
verspreiding van geïnjecteerd plaatjes-rijk plasma (PRP) in het midden van de Achilles 
pees. We maten de verspreiding van de geïnjecteerde vloeistof na 100 enkel manipu-
laties en na 15 minuten rust post-injectie in een kadaver studie. In alle tien de Achilles 
pezen werd een geleidelijke verspreiding van geïnjecteerd PRP gezien. Er was geen 
verschil in intratendineuze (in de pees) en peritendineuze (rond de pees) verspreiding 
tussen de twee post-injectie protocollen.
In de prospectieve cohort studie in hoofdstuk 4 werd gebruik gemaakt van een grote 
database van drie klinische studies, met meer dan 500 gekoppelde metingen. Er werd 
geen relatie gevonden tussen de hoeveelheid pijn en met echografie gemeten neovas-
cularisatie in symptomatische pezen. Neovascularisatie was helemaal niet aanwezig in 
24% van de pijnlijke achillespezen. Langere duur van de klachten was niet gerelateerd 
aan meer neovascularisatie. Afname van neovascularisatie gedurende de follow-up 
periode tot een jaar, was niet gerelateerd aan een betere klinische uitkomst (verbetering 
VISA-A score).
Het eerste doel van de case-control studie in hoofdstuk 5 was om echografische geme-
ten structuur van de achillespezen van type 1 en typ 2 diabetes patiënten te vergelijken 
met gezonde leeftijds-gematchte controles. Tweede doel was om een huid autofluores-
centie (AF) meting (wat de mate van versuikering van de huid aangeeft) te correleren 
aan de echografische achillespees. De studie liet zien dat patiënten met type 2 diabetes, 
en mogelijk ook patiënten met type 1 diabetes, een licht verminderde achillespees 
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structuur hebben dan de gezonde controles van dezelfde leeftijd. Hoewel patiënten 
met diabetes mellitus verhoogde AF-scores hadden vergeleken met hun controles, was 
het verschil in echostructuur hier niet door te verklaren. Groote voorspellende waarde 
voor echografische peesstructuur bleek de body-mass index (BMI).
hoofdstuk 6.1 en 6.2 bevatten de één-jaars- en vijf-jaars follow-up van een prospectieve 
gerandomiseerde studie naar het effect van excentrische oefentherapie vergeleken met 
dezelfde excentrische oefentherapie in combinatie met het dragen van een nachtspalk 
bij patiënten met mid-portion achilles tendinopathie. Excentrische oefentherapie, mét 
en zonder nachtspalk, verbeterde de functionele uitkomst na één jaar. Er was geen 
significant effect van het gebruik van een nachtspalk naast de excentrische oefenin-
gen. Tussen de één-jaars follow-up en de vijf-jaars follow-up was er een continuerende 
verbetering van de functionele uitkomst (verbetering van de VISA-A score) Tussen 
het afronden van het excentrische oefenprogramma na drie maanden en de vijf-jaars 
follow-up, had bijna de helft van de patiënten andere therapieën ondergaan. Slechte 
40% van de patiënten gaf aan volledig pijnvrij te zijn bij de vijf-jaars follow-up.
Het doel van de follow-up studie van een dubbelblind gestratificeerde gerandomiseerde 
gecontroleerde studie, beschreven in hoofdstuk 7, was om het klinische en echo-
grafische effect van plaatjes-rijk plasma injectie versus placebo-injectie na één jaar te 
evalueren in patiënten met chronische midportion achilles tendinopathie. Een injectie 
met plaatjes-rijk plasma als toevoeging op excentrische oefentherapie resulteerde niet 
in een betere klinische uitkomstmaat of echo structuur, vergeleken met een placebo 
injectie.
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Suzan de Jonge werd geboren op 3 januari 1984 te Oost-Souburg, gemeente Vlissingen. 
Van 1996 tot en met 2002 doorliep zij het atheneum aan het Erasmus College in Zoeter-
meer. Hierna startte zij de studie geneeskunde aan de Universiteit van Leiden, waar zij 
in 2003 haar propedeuse behaalde. Voor haar afstudeeronderzoek heeft zij 3 maanden 
stage gelopen op de afdeling Sportgeneeskunde in het Medisch Centrum Haaglanden 
te Leidschendam onder begeleiding van dr. Hans Tol, waarna in februari 2007 het docto-
raal werd verkregen. Het artsexamen legde zij in maart 2009 af.
Vanaf juni 2009 werd zij door Prof. dr. Jan Verhaar en Prof. dr. ir. Harrie Weinans aan-
gesteld als promovendus op het reeds bestaande peesproject in het Erasmus Medisch 
Centrum te Rotterdam. Dit promotietraject gecombineerd met de opleiding Sportge-
neeskunde heeft geleid tot de totstandkoming van dit proefschrift. In mei 2014 volgde 
zij een travelling fellowship van The European College of Sport and Exercise Physicians 
(ECOSEP) in vijf Europese steden.
Suzan de Jonge woont sinds oktober 2009 samen met Arjen Joosse in Leiden. Mo-
menteel is zij werkzaam als arts-assistent Sportgeneeskunde in het Medisch Centrum 
Haaglanden, locatie Antoniushove te Leidschendam onder hoofdopleider drs. Robert 
van Oosterom.
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Summary of PhD training and teaching activities
Name PhD student: S. de Jonge
Erasmus MC Department: Orthopaedic Research Laboratory
PhD period: 2009-2015
Promotors: Prof.dr.ir. H. Weinans, Prof.dr. J.A.N. Verhaar
Supervisors: dr. J.L. Tol
year ects
1. phd training
in-depth courses
Introduction to data-analysis (NIHES) 2010 5.7
Biomedical English Writing and Communication (EUR) 2011 4.0
Basiscursus Regelgeving & Organisatie voor Klinisch onderzoekers (BROK) 2011 4.0
Masterclass Medical Business 2013 0.3
(inter)national conferences: invited lectures
Het effect van een Plaatjes-Rijk Plasma injectie in chronische midportion 2010 1.0
Achilles Tendinopathie. Een dubbelblind gerandomiseerd placebo-gecontroleerd 
klinisch onderzoek met 1-jaars follow-up.
ZWOT bijeenkomst, 1 maart 2010, Rotterdam
Platelet-Rich Plasma as a treatment for tendon injuries. 2010 1.0
FA Elite Football Medicine Conference, 12 October 2010, London, Great Britain
PRP and tendinopathies: Cons 2012 1.0
15th ESSKA Congress, 03 May 2012, Geneva, Switzerland
Imaging and (injection) treatment in midportion Achilles tendinopathy 2014 0.5
16th Annual Scientific Conference in SEM QMUL CSEM in association with
European College of Sport and Exercise Physicians , 4 September 2014,
London, Great Britain
(inter)national conferences: podium presentations
The additional value of splinting to eccentric exercises in chronic midportion 2008 0.5
Achilles Tendinopathy: a randomized controlled trial with one-year follow-up
International Federation of Orthopaedic Manipulative Therapists (IFOMT),
13 June 2008, Rotterdam
One-year follow-up of a randomised controlled trial on added splinting to 2008 0.5
Eccentric exercises in chronic midportion Achilles tendinopathy
VSG congres “Sport, Bewegen & Gezondheid”, 28 November 2008,
Noordwijkerhout
Inter- en intra observer betrouwbaarheid Ultrasonographic Tissue 2009 0.5
Characterisation (UTC)
VSG congres “Sport, Bewegen & Gezondheid”, 4 December 2009,
Noordwijkerhout
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Awarded 2nd best abstract price Stichting Sport & Orthopaedie
The effect of Platelet-Rich Plasma injection in chronic midportion Achilles 2010 0.5
tendinopathy: A double-blinded randomized placebo-controlled clinical trial
with 1-year follow-up
NVA-VSG congress ‘New Horizons in Arthroscopy’, 27 May 2010, Noordwijk
aan Zee, the Netherlands
The effect of Platelet-Rich Plasma injection in chronic midportion Achilles 2010 0.5
tendinopathy. A double-blinded randomized placebo-controlled clinical trial
with 1-year follow-up.
2nd Congress European College of Sport and Exercise Physicians 12th Annual
Scientific Conference in SEM QMUL CSEM, 10 September 2010, London, Great
Britain
The effect of Platelet-Rich Plasma injection in chronic midportion Achilles 2010 0.5
Tendinopathy. A double-blinded randomised placebo-controlled clinical trial
with 1-year follow-up.
Dutch Tendon Meeting, 22 September 2010, Rotterdam, the Netherlands
What about neovessels? Een database studie naar de correlatie tussen 2010 1.0
Neovascularisatie en kliniek.
VSG congres “Sport, Bewegen & Gezondheid”, 25 November 2010,
Noordwijkerhout, the Netherlands
Plaatjes-Rijk Plasma behandeling bij Achilles tendinopathie: een dubbelblind 
gerandomiseerde studie met één-jaars follow-up.
2010 0.5
VSG congres “Sport, Bewegen & Gezondheid”, 25 November 2010,
Noordwijkerhout, the Netherlands
Awarded best abstract price Stichting Sport & Orthopaedie
Plaatjes-Rijk Plasma behandeling bij Achilles tendinopathie: een dubbelblind 
gerandomiseerde studie met één-jaars follow-up.
2010 0.5
Landsteiner wetenschapsmiddag, 26 November 2010, Den Haag, the
Netherlands
Lange termijn follow-up van Achilles tendinopathie vijf jaar na excentrische 2011 1.0
oefentherapie
VSG congres “Sport, Bewegen & Gezondheid”, 02 December 2011, Kaatsheuvel,
the Netherlands
Type 2, But Not Type 1 Diabetes, Predisposes To Achilles Tendon Disintegration 2012 1.0
59th Annual Meeting ACSM, 2 June 2012, San Fransisco, USA
Determinants of early Achilles tendon degeneration in Diabetes patients 2012 0.5
VSG congres “Sport, Bewegen & Gezondheid”, 29 December 2012, Ermelo, The
Netherlands
Awarded 2nd best abstract price Stichting Sport & Orthopaedie
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(inter)national conferences: poster presentations
The additional value of a night splint to eccentric exercises in chronic 2007 1.0
midportion Achilles tendinopathy: a randomized controlled trial
Society for Tennis Medicine and Science World congress, February 2007,
Antwerpen, Belgium
The effect of Platelet-Rich Plasma injection in chronic midportion Achilles 2010 1.0
tendinopathy
Tendinopathy Symposium, 30 September and 1 october, Umea, zweden
Determinanten van vroege Achillespees-degeneratie bij Diabetes patiënten 2012 0.5
Landsteiner wetenschapsmiddag, 23 November 2012, Den Haag, the
Netherlands
occasional reviewer for
Physical Medicine and Rehabilitation 2010 0.15
British Medical Journal 2011 0.20
Physical Therapy in sport 2011 0.20
British Journal of Sports Medicine 2012 0.15
Health Research Board (HRB) Ireland 2014 0.15
Sports Medicine 2014 0.15
other
ECOSEP/Bauerfind Travelling Fellowship (5 weeks) 2014 6.0
- Invited lecture: Sports Medicine in The Netherlands
Sports Medicine Trainees meeting London , 3 September 2014, London,
Great Britain
- Invited lecture: ECOSEP-Bauerfeind travelling fellowship
Sports Medicine Trainees meeting London , 4 September 2014, London,
Great Britain
2. teaching activities Year ECTS
lecturing
Achilles tendinopathie 2010 0.5
college tweedejaars geneeskunde studenten
7 January 2010, Erasmus MC, Rotterdam, the Netherlands
The effect of Platelet-Rich Plasma injection in chronic midportion Achilles 2010 0.5
tendinopathy
onderwijs arts-assistenten Orthopaedie
14 July 2010, Erasmus MC, Rotterdam, the Netherlands
Onderwijs Minor “Orthopaedische Sporttraumatologie” Pees en ligament 2010 0.5
28 September 2010, Erasmus MC, Rotterdam, the Netherlands
College tweedejaars geneeskunde studenten: Achilles tendinopathie 2011 0.5
24 January 2011, Erasmus MC, Rotterdam, the Netherlands
Intra-tendineuze afwijkingen; beeldvorming en aangrijpingspunten voor 2011 0.5
behandeling
Wetenschappelijke Bijeenkomst VSG: Chronische Midportion tendinopathie
van de Achillespees
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1 February 2011, Cibit, Bilthoven, the Netherlands
Intra-tendineuze afwijkingen; beeldvorming en aangrijpingspunten voor 2011 0.5
behandeling
Onderwijs arts-assistenten Orthopaedie
2 February 2011, Erasmus MC, Rotterdam, the Netherlands
Onderwijs Minor “Orthopaedische Sporttraumatologie” Pees onderwijs 2011 0.5
19 September 2011, Erasmus MC, Rotterdam, the Netherlands
supervising practicals
Begeleiding review tweedejaars geneeskunde studenten, EMC 2009 0.5
“Conservatieve behandeling van peesaandoeningen: effecten van autologe
groeifactoren in tendinopathie?”
Begeleiding review tweedejaars geneeskunde studenten, EMC 2009 0.5
“Het effect van geslacht op Achilles tendinopathie: een systematische review”
Supervisie snuffelstage geneeskundestudent, AMC 2010 0.5
Correlatie neovascularisatie en klinische presentatie in Achilles tendinopathie
Supervisie wetenschapsstage geneeskundestudent, Universiteit Leiden 2011 0.5
Incidence Achilles tendinopathy in the general population
Jan 2011- Apr 2011
Supervisie wetenschapsstage geneeskundestudent, Universiteit Leiden 2012 1.0
Ultrasonographic tissue characterisation of human Achilles tendons
Feb 2012- Sep 2012
Supervisie wetenschapsstage geneeskundestudent, Universiteit Leiden 2012 0.5
Clinical implications of the VISA-A score
Sep 2012- Dec 2012
Supervisie wetenschapsstage geneeskundestudent, Universiteit Leiden 2013 1.0
Dose reponse relation between eccentric exercises and clinical outcome
Jul 2013-Dec 2013
3. other activities Year ECTS
board positions
Member of the board of registrars sports medicine (Juniorkamer VSG) 2011 4.0
- Guidelines & Science 2011-2013
- Chairman 2014-present
Member of the board of the Netherlands Association of Sports Medicine (VSG) 2014 3.0
Member workgroup “Coach, Cure & Care, healthcare in 2025” 2013-present 4.0
- Organisation Symposium Coach, Cure Care 08-10-2013 2013
- Oral presentation and organisation: Coach, Cure, Care 2025 2013
Discussion Meeting Dutch Association Sports Medicine: Healthcare in
2025, 27 November 2013, Ermelo, The Netherlands
- Organisation Symposium Coaching, who cares 19-01-2015 2015
national conferences
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Oral presentation: Anthropometric values as predictor for hamstring graft 2010 0.5
diameter in anterior cruciate ligament reconstruction
NVA-VSG congress ‘New Horizons in Arthroscopy’, 27 May 2010, Noordwijk
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